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ABSTRACT
Cutaneous T-cell lymphomas (CTCL) represent a group of non-Hodgkin lympho-
mas showing a growing incidence especially in the Western world. The mechanisms 
leading to the disease are largely unknown, diagnosis is diffi cult and therefore often 
delayed, and no curative therapy exists. CTCL presents with skin symptoms although 
the malignant cells are not derived of human skin but of human immune system 
instead. The malignant cells are mature T helper memory cells, and preferentially 
express cytokines characteristic to T-helper 2 (Th2) type immune response. Chromo-
somal instability is a typical feature of CTCL. Some secondary cancers occur in CTCL 
patients more often than in general population, the most common of which are lung 
cancers and non-Hodgkin lymphomas.
The aim of the study was to identify genes relevant to CTCL pathogenesis to clar-
ify the poorly understood pathomechanisms behind the disease group. The two most 
common subgroups of CTCL, mycosis fungoides (MF) and Sezary syndrome (SS), 
as well as the diffi cult to diagnose subcutaneous panniculitis like T-cell lymphoma 
(SPTL), were studied. To reveal the molecular pathogenesis underlying CTCL-associ-
ated lung cancer, CTCL-associated lung cancer samples were analysed moleculocy-
togenetically and compared to primary / reference lung cancer samples. Identifi cation 
of potential novel diagnostic markers as well as target molecules for therapy was a 
special focus of the study. To achieve this, patient derived material was studied with 
molecular cytogenetic techniques, microarrays and gene expression analysis.
This study identifi ed the fi rst specifi c recurrent common gene level aberration in 
CTCL, namely the deletion / translocation of neuron navigator 3 (NAV3) in chromo-
some 12q21 occurring in 50% of patients with early CTCL and in 85% of patients 
with advanced CTCL. NAV3 is hypothesized to function as a non-classical, i.e. hap-
loinsuffi cient tumor suppressor infl uencing the differentiation of T-helper cells by 
increasing the production of cytokine interleukin-2. NAV3 deletion was observed in 
many CTCL subgroups (MF, SS, and SPTL), and its demonstration by FISH-technol-
ogy provides a novel diagnostic aid. Also additional chromosomal hot spots of loss 
and gain were identifed, with both DNA and RNA copy numbers changing to the 
same direction. Future studies will concentrate mainly on these areas to search for 
further target genes in CTCL. 
With microarray technology changes in gene expression were identifi ed, which 
could clarify the CTCL pathogenesis. A panel of genes with a central role in Th1-type 
immune responses, e.g. T-bet, RANTES, and NKG7, was downregulated in CTCL, thus 
explaining the previous observation of the Th2 type cytokine profi le of CTCL cells. 
Moreover, overexpression of potential target molecules for antibody-based therapy, 
e.g. membrane antigens MS4A4A, LIR9 and CD52, was identifi ed.
11
For the fi rst time, CTCL-associated lung cancers were observed to show chro-
mosomal aberrations differing from primary lung cancers. Especially amplifi cations 
of chromosome arm 4q and selected receptor tyrosine kinase genes (KIT, PDGFRα, 
and VEGFR2) in 4q12 found in CTCL-associated lung cancers were of interest, since 
chromosome arm 4q is frequently deleted in primary lung cancer. These preliminary 
observations warrant further prospective studies to identify the common underlying 
factors between CTCL and CTCL-associated lung cancer.
To conclude, NAV3 gene aberrations are common to many different CTCL sub-
types, and the pathways affected by its aberrant function, are currently being stud-
ied. Novel insights to CTCL pathogenesis were achieved through the observation that 
several genes specifi c for Th1 type immune response are downregulated in CTCL. 
Moreover, the fi nding of the difference in genomic aberrations of CTCL-associated 
and reference lung cancers raises a question whether cancer stem cells also have a role 
in the pathogenesis of CTCL. Demonstration of NAV3 deletion by FISH provides a 
novel diagnostic tool, and overexpression of certain membrane antigens will provide 
the basis for developing novel therapeutic means.
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1. REVIEW OF THE LITERATURE
1.1 Genes, chromosomes and cancer
1.1.1 General introduction
Current concept of cancer development includes the development of chromosomal 
instability, chromosomal number changes and a series of acquired genetic aberra-
tions affecting genes important for the growth and survival properties of the cell. The 
most important properties of malignancies are considered to be clonal cell growth 
and invasive ability (Fearon and Vogelstein, 1990). According to Kinzler and Vogel-
stein there are fi ve different types of genetic alterations in tumor cells: 1) subtle al-
terations, such as small deletions, insertions and mutations, 2) chromosome number 
changes, i.e. aneuploidy, 3) chromosomal translocations, 4) amplifi cations of small 
regions of chromosomes or single genes, and 5) exogenous sequences derived from 
tumor viruses (Kinzler and Vogelstein, 1998). Hanahan and Weinberg (2000) have 
proposed six principles defi ning cancer, namely 1) self-suffi ciency in growth signals, 
2) insensitivity to negative growth signals, 3) capability to evade programmed cell 
death, 4) capacity for sustained proliferation, 5) angiogenesis, and 6) tissue invasion 
and metastasis. Several different deregulated genes and pathways are involved in car-
cinogenesis (Hanahan and Weinberg, 2000). However, two main categories among 
genes with major effect on tumor initiation are identifi ed, namely oncogenes and 
tumor suppressor genes (Fearon and Vogelstein, 1990), and a certain gene may have 
both of these functions (Yang et al., 2007). Today, cancer is recognized as a multistep 
process in which the number of genetic hits rather than their order is essential. Ac-
cording to Vogelstein and Kinzler (2004) at least fi ve different genetic changes are 
required for a cancer to develop. Moreover, the genetic defects target more precisely 
different pathways than different genes (Vogelstein and Kinzler, 2004).
1.1.2 Oncogenes and tumor suppressors
Oncogenes are altered forms of normal cellular genes, called proto-oncogenes. In 
human cancers, proto-oncogenes are often located adjacent to chromosomal break-
points and are targets for mutation. According to current knowledge, activation of 
several oncogenes and inactivation of several tumor suppressor genes are necessary 
for the acquisition of a complete neoplastic phenotype. Oncogenes regulate main cel-
lular functions, e.g. cell cycle, cell differentiation and cell division. Oncogenes may 
act by rescuing the cells from senescence and apoptosis, thus blocking the cell dif-
ferentiation, or by reducing the growth factor requirements resulting in a continuous 
proliferative response. 
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Oncogenes are activated through chromosomal translocations, gene amplifi ca-
tions or gain-of function mutations (Bishop, 1991). Oncogenes act dominantly at 
cellular level, meaning that a mutation in one of the two oncogene alleles is suffi cient 
to lead to its increased activity. To date, more than 100 oncogenes have been identifi ed 
(Bishop, 1991; Rabbitts, 1994; Futreal et al., 2004). 
In contrast to oncogenes, classical tumor suppressor genes act recessively at cel-
lular level, meaning that two mutational events are required for the cancer develop-
ment (Knudson, 1971). The fi rst mutation may be inherited or somatic, whereas the 
second mutation is often achieved through a gross chromosomal mechanism, such 
as deletion, gene conversion, mitotic recombination resulting in loss of heterozygos-
ity (LOH), or through epigenetic mechansims (Devilee et al., 2001; Tomlinson et al., 
2001; Jones and Baylin, 2002). Approximately 30 classical tumor suppressor genes 
have been identifi ed thus far, including well-known genes for the pathogenesis of 
different cancer types, such as retinoblastoma 1 (RB1), von Hippel-Lindau tumor 
suppressor (VHL), neurofi bromin 1 (NF1), adenomatosis polyposis coli (APC), and 
breast cancer 1 and 2, early onset (BRCA1 and BRCA2) (Futreal et al., 2001). 
In addition to the classical tumor suppressors, acting through biallelic inactivation 
of a tumor suppressor gene, other phenomena, for example haploinsuffi ciency (Quon 
and Berns, 2001; Sherr 2004), have been shown to contribute to tumorigenesis. For 
a haploinsuffi cient tumor suppressor gene, inactivation of only one copy of the gene 
is suffi cient for the suppressive effect. Examples of tumor suppressor genes acting in 
haploinsuffi cient manner include p27Kip1 (Fero et al., 1998), p53 (Venkatachalam et al., 
1998), PTEN (Trotman et al., 2003) and DMP1 (Inoue et al., 2001). Knock out studies 
on mice have demonstrated that in p53 hemizygous mice (p53 +/-) the tumors arise 
later than in homozygous mice (p53 -/-) but earlier and more frequently than in wild-
type mice (p53 +/+) (Venkatachalam et al., 1998). The degree of haploinsuffi ciency 
may vary among tumor suppressor genes, ranging from no apparent effect to weak 
or strong effects (Cook and McCaw, 2000; Quon and Berns, 2001). It is believed that 
the biallelic inactivation of a tumor suppressor gene contributes to tumor progres-
sion and more severe tumor susceptibility (Quon and Berns, 2001; Rossi et al., 2002). 
However, haploinsuffi ciency would allow the clonal expansion of cells that are hetero-
zygous for a tumor suppressor gene, and would thus increase the size of the target cell 
population available for subsequent mutations during the remaining course of tumor 
progression. Thus, some degree of haploinsuffi ciency may be required to generate a 
suffi ciently large target cell population for mutagenesis. (Quon and Berns, 2001) It is 
believed that many classical tumor suppressors may well manifest haploinsuffi cient 
effects, particularly when combined with collaborating mutations affecting additional 
tumor suppressors or oncogenes (Sherr, 2004).
MicroRNAs (miRNAs) are short, noncoding RNAs that posttranscriptionally 
regulate gene expression. To date, over 500 miRNA genes have been identifi ed in the 
human genome, and miRNAs have been found to be involved in the pathophysiology 
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of all types of analysed human cancers by functioning either as tumor suppressors or 
oncogenes. Additionally, miRNAs alterations may cause cancer predisposition. miR-
NAs are shown to control key cellular events, such as cell proliferation, differentia-
tion, and apoptosis (Calin et al., 2006). Thus, miRNAs profi ling by microarrays or 
quantitative PCR provides novel diagnostic and prognostic tools for cancer patients. 
(Barbarotto et al., 2008; Yang et al., 2008)
1.1.3 Cancer stem cells
According to a current prevailing hypothesis, the recurrence and dissemination of 
many cancers is dependent on a small population of cells forming the primary tumor, 
namely the cancer stem cells, which apart from being capable of self-renewal and 
proliferation, also contribute to drug resistance and express typical stem cell mark-
ers (Harris, 2004; Dean et al., 2005; Polyak and Hahn, 2006). Cancer stem cells are 
responsible for initiating and sustaining tumor growth but are predicted to be re-
fractory to current therapies which are designed to eradicate actively cycling cells. 
Changes in the surrounding specialized microenvironment (niche) of the tumor cells 
can also directly infl uence tumor growth (Polyak and Hahn, 2006). Cancer stem cells 
may arise as a malignant transformation of tissue-specifi c stem cells or from more 
differentiated cells that have acquired stem cell characteristics through subsequent 
de-differentation. Still another possibility is that bone marrow –derived CD34+ stem 
cells migrate to sites of tissue damage, where they become tissue-specifi c stem cells 
(Passegue et al., 2003; Borue et al., 2004; Bjerkvig et al., 2005; Polyak and Hahn, 2006). 
There is experimental evidence supporting all these pathways, and it may be, that in 
different tumour types, different pathways operate (Polyak and Hahn 2006). The fi rst 
cancer stem cell described was the leukaemia stem cell, and to date the existence of 
cancer stem cells has been proven in breast, brain, and gastrointestinal tumors (Sirard 
et al., 1996; Cobakeda et al., 2000; Al Hajj et al., 2003; Singh et al., 2003; Houghton et 
al., 2004; Li et al., 2007). 
1.1.3.1 Lung cancer stem cells
For lung cancer, a stem cell population giving rise to lung adenocarcinoma, has recently 
been identifi ed (Kim et al., 2005). However, small cell lung cancer (SCLC) progenitor 
cell has not been isolated yet, although there is evidence of the existence of a primi-
tive neuroendocrine cell giving rise to some subsets of SCLC (Watkins et al., 2003). 
Studies on SCLC mouse model have also shown a possible dysplastic precursor lesion 
containing small foci of neuroendocrine cell proliferation and expressing markers for 
neuroendocrine differentiation (Meuwissen et al., 2003; Calbo et al., 2005). Also, it 
has been shown recently, that fetal lung mesenchymal stem cells can differentiate into 
neural cells in addition to the mesenchymal differentiation (Fan et al., 2005).
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1.1.3.2 Cancer stem cells in the skin
To date, there is emerging evidence of the stem cell origin of some cutaneous malig-
nancies, especially squamous cell carcinoma and melanoma (Kamstrup et al., 2007). 
Squamous and basal cell carcinomas are believed to arise from stem cells locating in 
the hair follicles and, to a lesser degree, in the basal layer of interfollicular epidermis 
(Blanpain et al., 2004; Tumbar et al., 2004). Studies on mouse models have demon-
strated the squamous cell carcinomas to occur when the oncogenic HRAS gene is ex-
pressed in the stem cells within the hair follicle but not, if other cells of the epidermis 
are targeted (Brown et al., 1998). Another study reported that mice, in which the in-
terfollicular epidermis had been removed, developed carcinomas as often as the intact 
mice (Morris et al., 2000). In basal cell carcinoma, a subset of cells escaping from the 
blockage of the Hedgehog signalling pathway and thus maintaining their capacity of 
tumor formation, has been recognized (Hutchin et al., 2005). As melanoma cells are 
capable of expressing neural markers (Rasheed et al., 2005), the association between 
nervous system tumors and melanoma in certain individuals, is believed to represent 
an underlying abnormality in neural crest stem cells (Fang et al., 2005). Moreover, 
metastatic melanoma has been shown to recur from a common progenitor cell (Wang 
et al., 2006).
No CTCL progenitor cell has been isolated so far, although there are preliminary 
reports of the initial malignant transformation to occur in bone marrow in a low-
grade cutaneous lymphoma, namely lymphomatoid papulosis (Gniadecki et al., 2003; 
Gniadecki, 2004). It has been speculated that bone marrow –derived stem cells would 
migrate to the site of chronic skin infl ammation (like Parapsoriasis en plaques), often 
preceding CTCL, and then either fuse with mutated lymphocytes in the skin or un-
dergo malignant transformation by themselves (Kamstrup et al., 2007). 
1.1.4 Epigenetic progenitor origin of cancer
In accordance with the cancer stem cell model, a recent theory suggesting the epige-
netic progenitor origin of human cancer has been proposed (Feinberg et al., 2006). 
Epigenetic refers to heritable information related to gene function not encoded in 
the nucleotide sequence (Baylin and Ohm, 2006; Feinberg et al., 2006). Epigenetic 
mechanisms include global changes such as histone modifi cations and gene-specifi c 
hypo- or hypermethylation of CpG dinucleotide islands resulting in gene activation 
or silencing, respectively (Herman et al., 2003; Issa et al., 2004). According to the epi-
genetic progenitor model of cancer, cancer arises in three steps (Feinberg et al., 2006). 
First, polyclonal epigenetic alterations occur in stem / progenitor cells within a cer-
tain tissue. These early epigenetic alterations predispose cells to genetic abnormalities. 
Second, an initiating monoclonal genetic mutation occurs within the subpopulation 
of the epigenetically disrupted cells. Third, genetic and epigenetic instability leads to 
tumor increased tumor evolution. 
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1.2 Primary cutaneous T-cell lymphoma (CTCL)
Primary cutaneous lymphomas represent a heterogeneous group of non-Hodgkin 
lymphomas (NHL) with homing preference to skin. After the gastrointestinal NHL’s, 
skin lymphomas are the second most common type of NHL’s. The annual incidence 
of CTCL is estimated 2,5 per 100000 for men but it is continuously increasing and 
affecting even younger people (Weinstock and Horn, 1988; Hartge et al., 1994; Siegel 
et al., 2000; Väkevä et al., 2000). CTCL is characterized by poorly known etiopatho-
genesis, diffi cult diagnosis and lack of curative therapy.
1.2.1 Classifi cation of cutaneous T-cell lymphomas
The classifi cation of cutaneous lymphomas is currently based on the World Health 
Organization - European Organization of Research and Treatment of Cancer (WHO-
EORTC) classifi cation (Willemze et al., Blood, 2005). The majority (75%) of the skin 
lymphomas are T-cell lymphomas, whereas skin lymphomas of B-cell origin com-
prise approximately 25% of all cutaneous lymphomas. The basis of the classifi cation 
is to divide skin lymphomas into T-cell and B-cell origin, and thereafter into indolent 
and aggressive clinical behaviour. The most common form of cutaneous lymphomas 
is mycosis fungoides (MF), comprising 44% of all cutaneous lymphomas. The WHO-
EORTC classifi cation of cutaneous T-cell lymphomas is shown in Table 1, and the 
subtypes that were studied in this thesis are characterized in more detail below.
Table 1. WHO-EORTC classification of cutaneous T-cell lymphomas with disease frequency and survival
Indolent clinical behaviour Frequency, %* Disease-specific 5-year survival, %
Mycosis fungoides (MF) 44 88
Folliculotropic MF 4 80
Pagetoid reticulosis <1 100
Granulomatous slack skin <1 100
Primary cutaneous anaplastic large cell lymphoma 8 95
Lymphomatoid papulosis 12 100
Subcutaneous panniculitis-like T-cell lymphoma 1 82
Primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma 2 75
Aggressive clinical behaviour
Sezary syndrome 3 24
Primary cutaneous NK/T-cell lymphoma, nasal-type <1 NA
Primary cutaneous aggressive CD8+ T-cell lymphoma <1 18
Primary cutaneous /  T-cell lymphoma <1 NA
Primary cutaneous peripheral T-cell lymphoma, unspecified 2 16
* Data are based on 1905 patients with a primary cutaneous lymphoma registered at the Dutch and Austrian Cutaneous 
Lymphoma Group between 1986 and 2002.
NA = not available
1.2.1.1 Mycosis fungoides (MF)
Mycosis fungoides is the most common form of cutaneous lymphomas comprising 
almost half of all primary cutaneous lymphomas. MF typically affects older adults 
(median age at diagnosis 55-60 years), and male-to-female ratio is 1.6-2.0:1 (Zack-
heim et al., 1999; van Doorn et al., 2000; Kim et al., 2003; Willemze et al., 2005). 
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Clinically MF presents classically with the evolution of skin lesions from patches to 
plaques and tumors mainly affecting trunk and other sun-protected areas (Alibert, 
1806; Bazin, 1852; Figure 1A). The diagnosis of MF is diffi cult, since it often resem-
bles eczema or mild psoriasis in its earliest stages. Often long-lasting observation of 
the clinical picture together with multiple skin biopsies are required to reach the MF 
diagnosis. Histologically, MF is characterized by the epidermotropic infi ltration of 
small to medium-sized malignant T-lymphocytes with a cerebriform nucleus (Figure 
1B). In early MF lesions, the number of the morphologically malignant cells is low 
and they are surrounded by reactive lymphocytes. Thus, reaching the diagnosis of-
ten implies multiple consequtive biopsies (Olsen et al., 2007). Clusters of malignant 
cells in papillary dermis (Pautriers’ microabscesses) are highly specifi c, although un-
common feature of MF. The immunophenotype of malignant cells is usually CD3+, 
CD4+, CD8-, CD45RO+, CD30-, although some variants with other immunopheno-
typic features also exist. The malignant cells are reported to be mature Th1 memory 
cells (Saed et al., 1994). The T-cell receptor genes are clonally rearranged in most 
cases, but for diagnostic purposes the TCR-gene rearrangement analysis in unspecifi c 
(Lukowsky et al., 2000; Sawabe et al., 2000)
Further staging of MF is achieved by criteria proposed by North American MF 
Cooperative Group (Bunn et al., 1979; Girardi et al., 2004) recently revised by the In-
ternational Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma 
task force of the EORTC (Olsen et al., 2007). MF is divided into four stages based on 
skin, nodal, visceral and blood involvement as defi ned by TNM (tumor-node-metas-
tasis) classifi cation (Bunn et al., 1979).
MF has an indolent clinical course and the disease progresses slowly. The estimat-
ed 5-year survival is 88% (Willemze et al., 2005). In advanced stages progression to 
a CD30+ or CD30- large cell T-cell lymphoma may be present (Cerroni et al., 1992). 
The treatment is based on the stage (IA-IVB) of the disease. Aggressive therapy does 
not improve the prognosis or remission time. Skin-directed therapy usually leads to 
remissions in the early stages. The duration of remissions is variable and most patients 
will suffer from a relapse. MF confi ned to skin is treated with photo(chemo)therapy: 
UVB irradiation and PUVA, whereas combination chemotherapy is recommended 
for systemic CTCL (stage IV). (Dummer et al., 2003; Whittaker et al., 2003; Trautinger 
et al., 2006) 
1.2.1.2 Sezary syndrome (SS)
Sezary syndrome (SS) is the leukaemic form of CTCL, where malignant T lymphocytes 
circulate in the blood (Sezary et al., 1938). SS can develop from pre-existing MF or 
arise de novo. Clinically, SS is characterized by pruritic erythroderma, lymphadenop-
athy, palmoplantar hyperkeratosis, alopecia, and onychodystrophy (Figure 1C). The 
diagnostic criteria of Sezary syndrome aim especially at differentiating it from bening 
erythrodermic conditions, and include one or more of the following: an absolute Se-
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zary cell (Figure 1D) count of least 1000 cells/mm3, the ratio of CD4/CD8 > 10, loss of 
any T-cell antigen (CD2, CD3, CD4, CD5), or the demonstration of a T-cell clone in 
peripheral blood by moleculocytogenetic methods or showing a clonal T-cell receptor 
rearrangement (Vonderheid et al., 2002; Willemze et al., 2005). Histologically, SS re-
sembles MF, although epidermotropism may be absent and the malignant T-cells may 
have lost their surface antigens to variable extent. The immunophenotype is similar 
to MF, but circulating Sezary cells may show loss of CD7 and CD26 (Vonderheid et 
al., 2002; Willemze et al., 2005). The tumor cells are usually CD3+, CD4+, CD8-, 
CD45RO+, CD30-, and mature Th2 memory cells (Vowels et al., 1992, Saed et al., 
1994; Dummer et al., 1996; Willemze et al., 2005). The prognosis in SS is poor, 5-year 
survival being only 24% (Table 1). No curative therapy exists, but therapy recommen-
dations include extracorporeal photopheresis either alone or in combination with e.g. 
interpheron-alpha, or interpheron alpha either alone or in combination with PUVA. 
New treatment modalities are developed continuously. The most recent options for 
refractory MF or SS include the rexinoid bexarotene, CD52 antibody alemtuzumab, 
and histone deacetylase inhibitor vorinostat. Bexarotene and alemtuzumab have been 
in clinical use in Finland during the last fi ve years, and vorinostat has recently been 
accepted to treat CTCL in the USA and is in clinical trials in Finland. (Dummer et al., 
2003; Whittaker et al., 2003; Rafandi et al., 2006; Trautinger et al., 2006; Gniadecki et 
al., 2007; Mann et al., 2007) 
1.2.1.3 Subcutaneous panniculitis-like T-cell lymphoma (SPTL)
Subcutaneous panniculitis-like T-cell lymphomas (SPTL) are a rare and poorly char-
acterized subgroup of cutaneous T-cell lymphomas (CTCL). The latest WHO-EORTC 
classifi cation separated for the fi rst time two different subgroups within SPTL (Wil-
lemze et al, 2005). Of these, only SPTL, with α/β T-cell phenotype (SPTL-AB), pre-
senting with cells usually expressing CD8 and restricted to the subcutaneous tissue, 
should be considered SPTL. In the γ/δ T-cell phenotype SPTL (SPTL-GD), the infi l-
trating malignant cells usually are CD8- and CD56+, may show (epi)dermal involve-
ment, and should be classifi ed among the cutaneous γ/δ T-cell lymphomas (Willemze 
et al., 2005; Willemze et al., 2008). 
Clinically, SPTL presents with solitary or multiple subcutaneous nodules and 
plaques, predominantly affecting the lower extremities and trunk (Figure 1E). Initial 
systemic symptoms like fever, fatigue and weight loss are frequent, and hemophago-
cytic syndrome (HPS) may be present (Gonzalez et al., 1991), indicating a rapidly 
progressive course and worse prognosis (Marzano et al., 2000; Willemze et al., 2008). 
Histologically, SPTL is characterized by subcutaneous infi ltrates of pleomorphic, small 
to medium-sized T lymphocytes rimming the individual fat cells, while the epidermis 
and dermis are typically uninvolved (Figure 1F). Additionally, necrosis, karyorrhexis, 
leukocytoklasia, and cytophagocytosis are often present. The immunophenotype is 
usually CD3+, CD4-, CD8+, CD56-, and cytotoxic proteins are frequently expressed. 
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The disease response to therapy is usually favourable with a 5-year survival of more 
than 80% (Massone et al., 2004, Willemze et al., 2007), without HPS even 91% (Wil-
lemze et al., 2008). 
Figure 1. Clinical and histological characteristics of mycosis fungoides (1A-B), Sezary 
syndrome (1C-D), and subcutaneous panniculitis-like T-cell lymphoma (1E-F).
1.2.2 Chromosomal, genetic and transcriptional aberrations 
characterizing CTCL
1.2.2.1 Chromosomal aberrations in CTCL 
Chromosomal aberrations can be classifi ed as numerical or structural. Numerical 
aberrations are the most common cytogenetic changes (Krämer et al., 2002). They 
are caused by defective segregation of chromosomes and can be seen as multiples of 
haploid chromosome number or extra or missing chromosomes. Structural chromo-
some aberrations include deletions, translocations, inversions, and multiplications of 
parts of the chromosome.
Studies on chromosomal aberrations of CTCL patients’ chromosomes have pro-
vided large number of information on both clonal and non-clonal nature of the chro-
mosome changes. Any chromosome can be aberrated, numerically or structurally. 
Early conventional cytogenetic techniques, like G-banding have been complemented 
with multicolor-FISH (including multifl uor-FISH, MFISH; spectral karyotyping, 
SKY; and COmbined Binary RAtio labelling FISH, COBRA-FISH), and cross-species 
color banding (RxFISH).
The fi rst cytogenetic studies utilized mainly G-banding technique and were per-
formed mostly on blood lymphocytes. Whang-Peng and coworkers reported numeri-
cal chromosome abnormalities especially in chromosomes 11, 21, 22, and 8, structur-
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al aberrations in chromosomes 1, 6, and 7, but the continuum went on involving all 
chromosomes (Whang-Peng et al., 1979 and 1982). These chromosome abnormalities 
were frequently detectable before morphologically neoplastic cells are encountered in 
blood (Whang-Peng et al., 1982). Karenko and coworkers described that numerical 
aberrations of chromosomes 6, 13, 15, and 17, marker chromosomes, and structural 
aberrations of chromosomes 3, 9, and 13 were increased in mycosis fungoides (MF) 
compared with healthy controls. The detection of a chromosomal clone preceded re-
lapse or progression of the disease (Karenko et al., 1997), and especially aberrations 
of chromosomes 8 and 17 associate with active or progressive disease (Karenko et al., 
2003).
Multicolor-FISH is a novel technology revealing structural chromosome aber-
rations not detectable with conventional cytogenetic methods, including balanced, 
complex translocations (see 3.2.3). In CTCL, frequently aberrated chromosomal ar-
eas include chromosomes 10 (in 7/9 patients), 6 (6/9), 3, 7, 9, 17, and 19 (5/9), 1 
and 12 (4/9), in which the majority of the abnormalities were structural (Batista et 
al., 2006). Moreover, recurrent breakpoints were observed in 1p32-p36, 6q22-q25, 
17p11.2-p13, 10q23-q26, and 19p13.3 (Batista et al., 2006), regions often showing 
DNA copy number losses in CGH studies (see 1.2.2.2; Karenko et al., 1999; Mao et al., 
2002; Fischer et al., 2004). 
Cross-species colour banding (Rx-FISH, Müller et al., 1997, 1998, 2002; Teixeira 
et al., 2000) is a coarse whole-genome screening method based on probes made of 
primate chromosomes, the DNA of which hybridizes to different human chromo-
somes forming bands. Espinet and coworkers used this technology in addition to the 
conventional cytogenetics, and revealed aberrations in chromosomes 10, 1, 6, 8, 9, 11, 
and 17 to be frequent in SS patients (Espinet et al., 2004).
Still another novel technology, COBRA-FISH (Tanke et al., 1999), which is based 
on the simultaneous use of combinatorial (binary) labelling and ratio labelling, has 
recently been used in CTCL research (Vermeer et al., abstract, 2006). Recurring struc-
tural chromosomal alterations in SS involved deletion of 10q24 (3 of 7 cases) and 
breakpoints at 17p11 (3 of 7 cases). (Vermeer et al., abstract, 2006)
Based on these studies on CTCL patients’ chromosomes, the most common chro-
mosomal aberrations involve chromosomes 1, 6, 10, and 17. However, these aberra-
tions are diverse.
1.2.2.2 DNA copy number gains and losses in CTCL
Since it is diffi cult to cultivate true CTCL cells, moleculocytogenetic methods which 
do not require cell cultivation, like comparative genomic hybridization (CGH) based 
on competitive hybridization of tumor and reference DNA on normal metaphase 
chromosomes or arrayed DNA fragments (see 3.2.1 and 3.3.1), are useful. Conven-
tional chromosomal CGH has revealed DNA copy number losses of chromosome 
arms 1p, 10q, 13q, 17p, 6q, and 19; and gains of 4q, 7, 8q, 17q, and 18 (Karenko et al., 
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1999; Mao et al., 2002; Fischer et al., 2004). In the German study, gain of chromosome 
arm 8q and loss of 6q and 13q correlated with a signifi cantly shorter survival, whereas 
some more frequent aberrations (loss in 17p and gain in 7) did not infl uence the 
prognosis (Fischer et al., 2004).
Genomic microarrays have been used to study the gene-level copy number aberra-
tions leading to CTCL. Mao and coworkers identifi ed several oncogene copy number 
gains with AmpliOnc I DNA Array containing 57 oncogenes, the most signifi cant of 
which was the amplifi cation of JUNB, detected in 5 of 7 cases with MF or SS studied. 
JUNB was also overexpressed in a larger series of CTCL patients (Immunohistochem-
istry or RT-PCR; Mao et al., 2003). The CGH of peripheral blood lymphocyte DNA 
of 21 SS patients on an array of approximately 3500 BAC-sequences (sensitivity 1Mb 
for deletions) performed by Vermeer and coworkers, revealed amplifi cations at 5p15 
(57%), 8q11 (48%), 8q24 (71%), 17q11 (71%), 17q21 (86%), 17q25 (71%), 19q13 
(29%) and 20q11 (24%) and deletions at 4q31 (38%), 5q22 (43%), 6q24 (29%), 
10q24 (52%) and 17p12 (67%). Amplifi cation of MYC (8q24) and deletion of p53 
(17p13), genes of interest to CTCL pathogenesis, were confi rmed at transcriptional 
level by quantitative PCR (Vermeer et. al., abstract, 2006). 
1.2.2.3 Epigenetic changes in CTCL
Recently, increasing evidence of the role of epigenetic changes has been recognized 
also in CTCL. As lymphomas in general show more frequent pattern of tumor sup-
pressor gene promoter hypermethylation compared to other cancers (Esteller et al., 
2001 and 2003), and as CTCL favourably responds to histone deacetylase (HDAC) 
inhibitor therapy (Piekarz et al., 2004), the epigenetic gene silencing is speculated to 
be important in CTCL. In CTCL, promoter hypermethylation of genes encoding CD-
KN2A (Navas et al., 2000 and 2002; Scarisbrick et al., 2002, Gallardo et al., 2004), CD-
KN2B (Scarisbrick et al., 2002; Gallardo et al., 2004), MLH1 (Scarisbrick et al., 2003), 
MGMT (Gallardo et al., 2004); BCL7A, PTPRG, TP73, and THBS4 (van Doorn et al., 
2005) has been reported, and in some cases revealed to associate with progressed dis-
ease (Navas et al., 2002; Scarisbrick et al., 2002; Gallardo et al., 2004). The fi rst drug 
belonging to histone deacetylase inhibitor group (vorinostat) has been recently ap-
proved in the U.S. for the treatment of CTCL not responding to other systemic modes 
of therapy (Mann et al., 2007). Vorinostat inhibits HDAC by binding to a zinc ion in 
the catalytic domain of the enzyme (Yoo et al., 2006) resulting in closed chromosomal 
confi guration and transcriptional repression (Bolden et al., 2006).
1.2.2.4 Gene expression profi ling of CTCL
Recently, gene expression profi ling by DNA microarray technology has been per-
formed, and several novel genes possibly having a role in CTCL pathogenesis have 
been discovered. Tracey and coworkers identifi ed an expression profi le suggesting up-
regulation of genes involved in TNF signaling pathway (e.g. TRAF1, BIRC3, TNFSF5) 
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among 29 MF skin samples when compared to infl ammatory dermatoses with the 
CNIO OncoChip array (Tracey et al., 2003). Kari and coworkers (2003) found overex-
pression of many Th2-specifi c transcription factors (like GATA-3 and JUNB), as well 
as RHOB, ITGB1 (integrin β1), and PRG2 (proteoglycan 2), while underexpressed 
genes included CD26, STAT4, and IL-1 receptors among 48 frozen PBMC samples of 
SS analyzed with a cDNA array containing 4500 genes. Altogether, a panel of 8 genes 
was identifi ed that could distinguish SS from normal controls, and 10 genes were able 
to classify patients into short term and long term survivors (Kari et al., 2003). In the 
blood samples of 10 Dutch SS patients, analyzed with Affymetrix U95Av2 array, de-
creased expression of some tumor suppressor genes such as TGFBR2 (TGF- β recep-
tor II) was shown, while EPHA4 and TWIST were overexpressed. The latter two were 
highly expressed also in some lesional skin samples of MF (van Doorn et al., 2004). 
1.2.2.5 Protein-level aberrations characterizing CTCL
The lack of accurate diagnostic tests for CTCL has lead to efforts to identify CTCL-
cell specifi c markers that would easily be applicable for diagnostic purposes. One of 
such novel molecular markers is T-plastin, a cytoplasmic protein regulating actin as-
sembly and cellular motility, which is expressed on Sezary cells but not on T-helper 
cells from healthy individuals or patients with non-malignant dermatoses (Su et al., 
2003). Some of the members of killer cell immunoglobulin-like receptors (KIR) that 
are normally expressed on a minor population of circulating NK and CD8+ T lym-
phocytes, namely CD158A/KIR2DL1, CD158B/KIR2DL3, and CD158K/KIR3DL2, as 
well as vimentin have also been suggested as diagnostic markers for circulating Se-
zary cells (Poszepczynska-Guigné et al., 2004; Huet et al., 2006; Ortonne et al., 2006, 
Marie-Cardine et al., 2007). 
The most important molecular genetic and epigenetic features of CTCL reported 
in the literature are summarized in Table 2. 
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Table 2. Overview of the most important molecular genetic and epigenetic changes reported in CTCL
Gene Mechanism CTCL subtype Presumed consequence Reference
BCL2 Deletion, MF, SS Altered apoptosis Nevala 2001; Kari 2003; Mao
underexpression 2004
BCL7a Promoter hyper- MF Tumor suppression van Doorn 2005
methylation
BIRC3 Overexpression MF Defective apoptosis, Tracey 2003
impaired TNF signaling
Caspase-1 Overexpression MF, SS Th2 up Yamanaka 2006
CD158a Overexpression SS Regulation of immune Marie-Cardine 2007
responses
CD158b Overexpression SS Regulation of immune Marie-Cardine 2007
responses
CD158k Overexpression SS Regulation of immune Bagot 2001
responses
CD26 Underexpression SS Skin homing Kari 2003; Narducci 2006; 
Jones 2001
CD40 Overexpression MF, SS Impaired TNF signaling Storz 2001; Kari 2003
CD40L Overexpression MF T-cell proliferation Tracey 2003
CDKN2A, p16 Promoter hyper- MF, SS Cell cycle regulation, Navas 2000 and 2002; 
methylation, LOH tumor suppression Scarisbrick 2002; van Doorn 2005
CDKN2B, p15 Promoter hyper- MF, SS Cell cycle regulation, Navas 2002; Scarisbrick 2002;
methylation, LOH tumor suppression van Doorn 2005
CTSB Amplification MF, SS Oncogenesis Mao 2003
CX3CR1 Overexpression SS Defective apoptosis Kari 2003
EphA4 Overexpression SS Oncogenesis van Doorn 2004
Fas Point mutation, MF, SS Defective apoptosis, Dereure 2000 and 2002; 
underexpression tumor suppression Nagasawa 2004; Kari 2003
GATA-3 Overexpression SS Th2 up Kari 2003
HRAS Amplification MF, SS Oncogenesis Mao 2003
IL1R1 Underexpression SS Defective apoptosis Kari 2003
ITGB1 Overexpression SS Skin homing Kari 2003
JUNB Amplification, MF, SS Th2 up Mao 2003; Kari 2003
overexpression
MLH1 Promoter hyper- MF Diminished DNA repair Scarisbrick 2003
methylation
MMP-9 Overexpression MF Angiogenesis Vacca 1997
MYC Amplification, MF, SS Oncogenic transcription Mao 2003; Vermeer 2006
overexpression factor
p53 Point mutation, dele- SS Tumor suppression, McGregor 1999; Vermeer 2006
tion, underexpression cell cycle regulation
PAK1 Amplification MF, SS Oncogenesis Mao 2003
PLS3 Overexpression SS Actin interactions Su 2003; Kari 2003
PTEN Deletion MF Tumor suppression Scarisbrick 2000
PTPRG Promoter hyper- MF Tumor suppression van Doorn 2005
methylation
RAF1 Amplification MF, SS Oncogenesis Mao 2003
RhoB Overexpression SS Actin interactions Kari 2003
STAT4 Underexpression SS Th1 down Kari 2003
TGF R2 Underexpression SS Defective tumor suppression van Doorn 2004
THBS4 Promoter hyper- MF Tumor suppression van Doorn 2005
methylation
TP73 Promoter hyper- MF Tumor suppression van Doorn 2005
methylation
TRAF1 Overexpression MF Defective apoptosis, Tracey 2003
impaired TNF signaling
Twist Overexpression SS Defective apoptosis, van Doorn 2004
oncogenesis
24
1.2.3 The biology of T-lymphocytes normally and in relation
to CTCL
1.2.3.1 Normal T lymphocyte development
Normally, naïve T lymphocytes develop and proliferate in thymus where they select 
their antigen specifi city by rearranging their T-cell receptor gene structure, and spe-
cialize to naïve cytotoxic (CD8+) or naïve helper (CD4+) T-cells (Petrie, 2003; Taka-
hama, 2006). After maturation in thymus, they circulate in blood and migrate to pe-
ripheral lymphoid organs, where they are activated by antigen presenting cells (APC; 
i.e. dendritic cells, macrophages, and B lymphocytes). T helper progenitor cells dif-
ferentiate into Th1 or Th2 direction in response to the cytokines secreted by the APC’s 
and the antigenic stimulus (Mosmann et al., 1986; Del Prete et al., 1991; Lahesmaa et 
al., 1992). Recently, still another subset of T-helper cells, termed Th17, has been rec-
ognised (Harrington et al., 2006; Weaver et al., 2006). The various factors infl uencing 
T helper cell differentiation are presented below and in Figure 2. Th1 cells function in 
cell mediated immunity and delayed hypersensitivity reactions and an increased Th1 
response plays a role in tissue damage and in various autoimmune conditions. Th2 
lymphocytes, instead, maintain the humoral immune response and are involved in 
the pathogenesis of asthma and atopic diseases. Th17 cells function during infections 
against extracellular bacteria and in some autoimmune diseases. (Abbas et al., 1996; 
Mosmann and Sad, 1996; Ray and Cohn, 1999; Romagnani, 1996; Wills-Karp, 1999; 
Singh et al., 1999; Reiner et al., 2007)
1.2.3.2 T helper cell differentiation
When unpolarized T helper progenitor cells encounter antigen presenting cells in 
lymph nodes, they interact through T-cell receptor of the T cell and MHCII class 
molecule of the APC. Various activation signals lead to the differentiation of the T 
cells either to Th1 or Th2 type T helper cells. The most important issue infl uenc-
ing the Th differentiation is the surrounding cytokine milieu, composed mainly of 
interleukins (Sher and Coffman, 1992). APC’s secrete cytokines, which together with 
the costimulatory molecules on the surface of T cells and APC’s lead to the differen-
tiation of T helper cells into Th1 and Th2 types. The major Th1 polarizing cytokine 
is interleukin (IL) -12, which acts via STAT4, and induces Th1 differentiation and 
production of Th1 specifi c cytokines, such as interferon (IFN) -γ, IL-2, and tumor 
necrosis factor (TNF) –β (Seder and Paul 1994; Jacobson et al., 1995). Also, IFN-α 
plays a key role in the Th1 differentiation by regulating STAT1. IL-4 is known to be 
the major cytokine leading to the Th2 phenotype of the unpolarized Th cells. IL-4 acts 
through STAT6, and results in the Th2 phenotype and production of cytokines IL-4, 
IL-13, IL-5, IL-9, IL-6, and IL-10. (Hou et al., 1994; Schindler et al., 1994; Seder and 
Paul 1994) All the factors that contribute to the T helper cell differentiation are not 
yet fully known, and the process is complex and several factors are known to inhibit 
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each other. IL-1 and IL-18 are costimulatory molecules that can increase production 
of both Th1 and Th2 type cytokines. IFN-α/β and IL-27 are involved in the initiation 
and maintenance Th1 response, whereas IL-13, IL-6, and IL-21 are required for the 
Th2 type immune response. Besides cytokines, also transcription factors infl uence T 
helper cell differentiation. Nuclear transcription factor T-bet leads to the Th1 pheno-
type by inducing and enhancing IL-12 signaling. On the other hand, GATA-3, that is 
activated through STAT6 or by autoactivation or by T cell activation signals, increases 
Th2 type cytokine production and even turns the Th1 committed T cells back to the 
Th2 direction. Th17 development is induced by the synergistic action of of IL-6 and 
IL-1β. (Zhang et al., 1997; Zheng and Flavell, 1997; Szabo et al., 2000; Bettelli et al., 
2006; Acosta-Rodriguez et al., 2007.) 
Figure 2. T-helper cell differentiation into Th1 and Th2 cells.
Differentiation of activated T helper cells to Th1 or Th2 direction is induced by IL-12 or 
IL-4 via STAT4 and STAT6 signaling, respectively, whereas synergistic action of IL-6 and 
IL-1β favors Th17 development. The cytokines produced by each T helper cell group and 
their functions in immune responses are shown. Modifi ed from Rengarajan et al., 2000.
1.2.3.3 T lymphocytes in CTCL
The cause, compartment and timing of malignant transformation of the T-lym-
phocytes in CTCL are not known (Veelken et al., 1995; MacKie et al., 1998; Burg et al., 
2001). The migration of Th memory cells to the skin is dependent on the interactions 
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of a large variety of molecules expressed on T-cells and other cells of the skin (Schön 
et al., 2003, Pals et al., 2007). While maturing, the T-cells start to express cutaneous 
lymphocyte-associated antigen (CLA), which through interactions with E-selectin 
leads their migration to skin (Meijer et al., 1989; Picker et al., 1990). Other molecules 
leading to skin homing are chemokine receptors 4 and 10 (CCR4 and CCR10), which 
have been shown to be expressed on CTCL cells often in combination with CXCR3 
(Ferenzi et al., 2002; Schön et al., 2003; Notohamiprodjo et al., 2005; Wenzel et al., 
2005). Interestingly, MF and SS show different homing signatures, corresponding to 
the different dissemination patterns of the two subgroups. The tumor cells in MF 
express low levels of peripheral lymph node homing receptor L-selectin and CCR7. 
During MF progression, the development of lymph node involvement is accompanied 
by a loss of skin-specifi c chemokine receptors and upregulation of CCR7 (Kallinich 
et al., 2003). In Sezary syndrome, on the contrary, the malignant T-cells coexpress the 
cutaneous and peripheral lymph node homing signatures, i.e. L-selectin and CCR7 as 
well as CLA and CCR4 (Sokolowska-Wojdylo et al., 2005), thus explaining the prefer-
ence of early lymph node involvement in SS.
Local T-cell growth factors, mainly interleukins, maintain T-cell proliferation in 
the skin. Autocrine IL-2, keratinocyte-derived IL-7, and APC-derived IL-15 are the 
most important growth factors promoting growth and survival of CTCL cells in vitro 
(Dalloul et al., 1992; Döbbeling et al., 1998). In later stages of CTCL, tumor cells may 
become independent of these exogenous signals, e.g. by autocrine production of IL-
15 or by interactions via STAT (signal transducers and activators of transcription) 
molecules (Asadullah et al., 2000; Qin et al., 1999, 2001). Disturbances in STAT signal-
ling pathways have been observed in CTCL, e.g. constitutive STAT3 activation (Zhang 
et al., 1996), loss of STAT1 and STAT4 protein expression (Tracey et al., 2002; Kari et 
al., 2003), and dysregulation of the balance between full-length and truncated forms 
of STAT5 (Mitchell et al., 2003), which affects the cell cycle progression (Moriggl et 
al., 1999). Despite the availability of the above-mentioned cytokines, it has proven 
to be diffi cult to cultivate CTCL cells in vitro. The lack of true CTCL cell lines may 
be explained by the complicated T-cell signalling, not yet fully understood, as well as 
some unknown epidermal stimuli, that the cells require. 
Based on initial studies on cytokine profi ling, it has been revealed that myco-
sis fungoides exhibits a Th1 type cell-mediated cytokine profi le whereas Sezary syn-
drome expresses a Th2-type profi le (Saed et al., 1994, Vowels et al., 1992). In later 
studies, the Th2 type cytokine profi le of SS was confi rmed, but reports on MF showed 
nonconsistent fi ndings with cytokine profi le favouring Th1 or Th2 polarization or no 
polarization (Vowels et al., 1994; Dummer et al., 1996; Harwix et al., 2000). Besides 
cytokine profi ling, also transcription factor level characteristics of CTCL have been 
revealed. Overexpression of GATA-3 and underexpression of STAT4 have been report-
ed in Sezary syndrome (Kari et al., 2003), whereas STAT4 overexpression characterizes 
MF (Tracey et al., 2003).
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Recently, reduced expression of IL-17 produced by the Th17 cells, has been ob-
served in late stages of MF with blood involvement (Chong et al., 2008).
Types of Th cells other than Th1, Th2 and Th17 have been identifi ed. These are 
called regulatory T cells (Tregs, previously called suppressor T cells) mediating im-
munosuppressive functions. Several subsets of Tregs exist, e.g. CD4+CD25+ Tregs, 
CD4+CD25- Tregs, Tr1 Tregs, Th3 Tregs, and NK Tregs (Beissert et al., 2005) mediat-
ing various functions, most importantly suppression of autoimmunity. According to 
one theory, CTCL would be a malignant proliferation of T regulatory cells (Berger et 
al., 2005). On the other hand, another theory suggests lack of functional regulatory 
(CD4+CD25+FOXP3+) T-cells in SS (Tiemessen et al., 2006).
1.2.4 CTCL-associated secondary cancers
Until now only a few epidemiological studies about CTCL-associated secondary can-
cers have been published. Kantor and coworkers discovered in 1989 an increased risk 
of lung and colon cancer, as well as other non-Hodgkin lymphomas among CTCL 
patients in a study covering a 10-year period in American population (Kantor et al., 
1989). Väkevä and coworkers performed a study on Finnish CTCL patients, based on 
the information collected from the Finnish Cancer Registry during the years 1953-
1995 (Väkevä et al., 2000). In a cohort of 319 Finnish CTCL patients, 12 patients were 
diagnosed to have lung cancer apart from CTCL. Half of the lung cancers were of 
microcellular and one fourth of squamous cell origin. Thus, lung cancer, especially 
small cell lung cancer (SCLC), was more common than in the general population with 
over 8,5-fold risk. Also, the risk of non-small cell lung cancer and other non-Hodgkin 
lymphomas was increased. The average time from CTCL diagnosis to lung cancer 
diagnosis was 6 years, but half of the SCLC cases occurred within one year after di-
agnosis of CTCL suggesting possible common biological factors. Environmental fac-
tors or treatment of CTCL could not explain the increased incidence of lung cancer. 
(Väkevä et al., 2000)
1.2.4.1 Lung cancer
Lung cancer, being mainly caused by cigarette smoking, is a leading cause of cancer-
related deaths worldwide, with approximately 1.2 million deaths annually (Parkin et 
al., 2005). Also in Finland, most cancer-deaths occur due to lung cancer and it is the 
second most common cancer among Finnish males and the fi fth most common can-
cer among Finnish females. In Finland and other developed countries, the incidence 
of lung cancer is decreasing among men but increasing among women. (http://www.
cancerregistry.fi ) Malignancies of the lung are divided into small cell (SCLC) and 
non-small cell lung cancers (NSCLC), the latter consisting of squamous cell carci-
noma (SCC, epidermoid carcinoma), adenocarcinoma, and large cell carcinoma. Es-
pecially SCLC is a rapidly proliferating and early metastasizing malignancy with poor 
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survival; median survival after treatment is 1 year (Worden et al., 2000). Recent stud-
ies have shown the genetic background to be different among these two cancer types 
(Wistuba et al., 2001; Fong et al., 2003; Kaminski et al., 2004).  
Interestingly, CTCL and SCLC share some histological similarities, as SCLC is 
composed of small, lymphocyte-like cells, with scarce cytoplasm and molded nuclei 
growing typically underneath the bronchial epithelium (Kumar et al., 1997). SCLC is 
considered to be derived from the neuroendocrine cells of the lung (Bunn et al., 1985), 
and shows different expression of genes related to neuroendocrine cell differentiation 
and/or growth compared to non-cancerous lung tissue cells (Taniwaki et al., 2006). 
Typically, in lung carcinomas, multiple chromosome aberrations can be observed in-
dicating genomic instability. SCLC and NSCLC differ from each other based on the 
molecular cytogenetic fi ndings, although some common abnormalities also exist. The 
most common shared CGH fi ndings include losses of genetic material from chro-
mosome arms 3p, 4q, 5q, 8p, 13q, and 17p, and gains of 3q, 5p, and 8q, while SCLC 
cases frequently show losses from 10q and 16q, and gains of 19q, whereas NSCLC is 
characterized by 9p losses and 1q gains (Balsara and Testa, 2002). When comparing 
previously reported molecular cytogenetic fi ndings of CTCL and lung cancer, espe-
cially SCLC shows some similarities with CTCL. Both CTCL and lung cancer (SCLC 
and NSCLC) frequently show DNA copy number losses of chromosome arms 13q 
and 17p, and gains of 8q. Additionally, CTCL and SCLC share the characteristic 10q 
loss (Karenko et al., 1999; Balsara and Testa, 2002; Mao et al., 2002, 2003; Fischer et al., 
2004). This might suggest common underlying genetic factors, possibly even a com-
mon cancer stem cell (Huntly et al., 2005; Kim et al., 2005; see 1.1.3).
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2. AIMS OF THE STUDY
The aim of the study was to identify novel chromosomal and genetic alterations in cu-
taneous T-cell lymphomas leading to the clarifi cation of CTCL pathogenesis and clas-
sifi cation, develop novel accurate diagnostic tools and identify candidate molecules 
for targeted therapy. The more detailed aims were to
  I. identify DNA copy number and gene expression aberrations typical of dif-
ferent CTCL subtypes, as well as to fi nd shared aberrations common to 
many subtypes
  II. identify genes important to CTCL pathogenesis, develop novel diagnostic 
tools and identify candidate molecules for the development of targeted 
therapy
  III. study CTCL-associated secondary cancers and reveal genomic changes be-
hind them in relation to primary CTCL or primary cancers occurring at the 
site of the secondary malignancies
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3. MATERIAL AND METHODS
All studies included in this thesis have been approved by the Ethical Review Boards of 
the Skin and Allergy Hospital, Helsinki University Hospital, and of Internal Medicine, 
The Joint authority of Helsinki and Uusimaa as indicated in the original publications. 
All patient material was collected with the patients’ (or parents’ in case of children) 
written informed consent.
3.1 Patient samples and preparation of research / study 
material (I-IV)
Altogether 48 CTCL samples (Table 3), 5 CTCL-associated lung cancer samples, and 
29 reference samples of healthy volunteers (studies I and II) or diseased individuals 
with either non-malignant infl ammatory skin disease (studies I and II) or primary 
lung cancer (study IV) were obtained. 
Table 3. CTCL patients studied in the thesis (Studies I-III)
Patient Diagnosis, sex and age Applied methods and tissue / cell type Study
1 SS (M65) CGH (PBMC), MFISH (PBMC), FISH (PBMC, ln) I
2 SS (M63) MFISH (PBMC), FISH (skin) I
3 SS (M53) CGH (PBMC), MFISH (PBMC), FISH (PBMC, skin) I
4 SS (F64) MFISH (PBMC) I
5 SS (M68) MFISH (PBMC) I
6 SS (M50) MFISH (PBMC) I
7 SS (M54) MFISH (PBMC) I
8 SS (M52) CGH (PBMC, skin), MFISH (PBMC), Array (PBMC), QPCR (PBMC), IHC (skin) II
9 SS (M63) CGH (PBMC, skin), MFISH (PBMC), Array (PBMC, CD4+), QPCR (PBMC), IHC (skin) II
10 SS (M72) CGH (PBMC, skin), MFISH (PBMC), Array (PBMC), QPCR (PBMC) II
11 SS (M72) Array (PBMC), QPCR (PBMC) II
12 SS (M58) QPCR (PBMC) II
13 SS (M74) QPCR (PBMC) II
14 SS (M59) IHC (skin) II
15 SS (M62) IHC (skin) II
16 SS (F56) CGH (PBMC), FISH (skin) I
17 MF IA (M42) MFISH (PBMC), FISH (skin), IHC (skin) I, II
18 MF IA (F79) CGH (skin), MFISH (PBMC), Array (PBMC, CD4+, skin), QPCR (PBMC, CD4+, skin) II
19 MF IA/B (M53) FISH (skin) I
20 MF IB (M58) CGH (skin), MFISH (PBMC), FISH (skin), Array (PBMC, CD4+, skin), QPCR (PBMC, CD4+, skin), IHC (skin) I, II
21 MF IB (M44) FISH (skin) I
22 MF IB (F48) FISH (skin) I
23 MF IB (F72) FISH (skin) I
24 MF IB (M76) FISH (skin), IHC (skin) I, II
25 MF IB (M20) MFISH (PBMC), FISH (skin) I
26 MF IB (F69) Array (PBMC), QPCR (PBMC) II
27 MF IB, CD30+ (M71) CGH (skin), MFISH (PBMC), Array (PBMC, CD4+, skin), QPCR (PBMC, CD4+), IHC (skin) II
28 MF IIB (M62) MFISH (PBMC), FISH (skin), IHC (skin) I, II
29 MF IIB (M48) MFISH (PBMC), FISH (skin) I
30 MF IIB (F56) MFISH (PBMC), FISH (skin), IHC (skin) I, II
31 MF IIB (F45) FISH (skin) I
32 MF IIB (M52) FISH (skin) I
33 MF IIB (F49) FISH (skin) I
34 MF III (M69) FISH (skin) I
35 MF IVA (M55) CGH (skin), FISH (skin), IHC (skin) I, II
36 MF IVA (M83) CGH (skin), FISH (skin) I
37 MF IVB (F45) Array (PBMC), QPCR (PBMC) II
38 MF (F73) QPCR (skin) II
39 MF (F59) QPCR (PBMC) II
40 SPTL (F18) CGH (skin) III
41 SPTL (M16) CGH (skin), FISH (skin), LOH (skin) III
42 SPTL (M13) CGH (skin), MFISH (PBMC), FISH (skin), LOH (skin) III
43 SPTL (M18) CGH (skin), MFISH (PBMC) III
44 SPTL (M23) CGH (skin), LOH (skin) III
45 SPTL (F48) CGH (skin), MFISH (PBMC), LOH (skin) III
46 SPTL (F59) III
47 SPTL (M27) FISH (skin) III
48 SPTL (F15) III
SS = Sezary syndrome, MF = mycosis fungoides, SPTL = subcutaneous panniculitis-like T-cell lymphoma, CGH = comparative genomic hy-
bridization, MFISH = multicolor fl uorescent in situ hybridization, FISH = fl uorescent in situ hybridization, Array = Affymetrix gene expression 
array, QPCR = real-time quantitative PCR, IHC = immunohistochemistry, LOH = loss of heterozygosity analysis, PBMC = peripheral blood 
mononuclear cell, CD4+ = CD4 positive lymphocyte, ln = lymph node
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3.1.1 Microdissection of tumor cells (III-IV)
Areas or single morphologically malignant cells (lymphocytes for Study III and lung 
carcinoma cells for Study IV) were laser capture microdissected using the P.A.L.M. 
Laser-Microbeam system (P.A.L.M. Microlaser Technologies). Sections of 5-µm were 
cut from the samples using a microtome and mounted onto a 1,35 µm thin polyeth-
ylene membrane (P.A.L.M. Microlaser Technologies, Bernried, Germany) attached to 
a glass slide. After deparaffi nization and hematoxylin staining, single or small areas 
(50000-200000 µm2) of morphologically malignant cells were laser capture microdis-
sected using the P.A.L.M. Laser-Microbeam system (P.A.L.M. Microlaser Technolo-
gies). Hematoxylin-eosin staining with standard protocol served as morphological 
control for microdissection. After proteinase K digestion, the DNA was amplifi ed 
with single cell comparative genomic hybridization (SCOMP) as previously described 
(Klein et al., 1999, Stoecklein et al., 2002; see 3.1.2.2). 
3.1.2 Nucleic acid isolation (I-IV)
3.1.2.1 DNA isolation using standard techniques
DNA was isolated from Ficoll-enriched blood samples, fresh-frozen or paraffi n-em-
bedded skin samples from CTCL patients and from control individuals diagnosed 
with an infl ammatory skin disease using standard procedures with phenol and chlo-
roform extraction (Sambrook, 1989).
3.1.2.2 DNA isolation after laser microdissection
After laser capture microdissection of morphologically malignant T lymphocytes 
(Study III) or lung carcinoma cells (Study IV), microdissected and proteinase K -
digested DNA was further digested with Mse I restriction enzyme (New England Bi-
oLabs, Ipswich, MA), adaptors were ligated to the 5’ overhangs, and DNA fragments 
were amplifi ed by polymerase chain reaction. The success of the amplifi cation was 
PCR-tested with microsatellite markers D5S500 and D17S1161, as previously de-
scribed (Stoecklein et al., 2002). The oldest paraffi n blocks with successful DNA isola-
tion and amplifi cation dated back to the 1970’s.
3.1.2.3 RNA isolation from PBMC, CD4+ cells and skin
PBMC from patients and healthy controls were isolated with density gradient cen-
trifugation (Ficoll-Paque PLUS, Amersham Biosciences, Uppsala, Sweden), and 
CD4+ cells were enriched with magnetic beads (CD4+ T-cell isolation kit or CD4+ 
microbeads, Miltenyi Biotech, Bergisch Gladbach, Germany). Total RNA was isolated 
with Trizol reagent (Invitrogen Life Technologies, Grand Island, NY). Fresh skin biop-
sies were immediately placed in RNA Later buffer (Ambion, Austin, TX) and homog-
enized in Trizol reagent and RNA was isolated.
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3.1.3 Cell preparates for FISH, MFISH and CGH (I-IV) 
Touch preparates for FISH analysis (see 3.2.2) were prepared from snap-frozen skin 
or lymph node biopsies of 23 patients with MF, SS, or SPTL, and 10 control samples of 
infl ammatory skin lesions. Briefl y, freshly cut tissue surface of snap-frozen (stored in 
liquid nitrogen or mounted in Tissue-Tek) tissue biopsies were gently pressed against 
a SuperFrost plus slide, air-dried and stored frozen until analyzed. Normal or patient-
derived PHA-stimulated peripheral blood lymphocytes were cultured for 3 days under 
standard conditions to yield high quality metaphases for CGH or MFISH analysis. 
3.2 Molecular cytogenetics
3.2.1 Comparative genomic hybridization (I-IV)
Since the development of comparative genomic hybridization (CGH) in the early 
1990’s (Kallioniemi et al., 1992), it has become one of the most widely used tech-
niques in cancer research. CGH is based on the competitive hybridization of DNA 
isolated from the tumor and reference DNA obtained from healthy individuals to 
normal metaphase chromosome slides. There is no requirement for metaphase prepa-
rations of malignant cells, which makes the technology especially feasible for studies 
of solid tumors, often diffi cult to cultivate. CGH enables identifi cation and localiza-
tion of DNA copy number aberrations of the whole genome in a single experiment. 
The main disadvantage of the technology is its limited resolution being 10-20 Mb 
for deletions and 1 Mb for amplifi cations (Kallioniemi et al., 1994; Bentz et al., 1998, 
Forozan et al., 1997). The sensitivity for deletions can be improved to 3 Mb by us-
ing standard reference intervals, based on a series of normal samples (Kirchoff et al., 
1999). The length of amplifi ed sequences that can be detected depends on the copy 
number so that the copy number times the amplicon size is at least 2 Mb (Kallion-
iemi et al., 1994). Polyploidy weakens the sensitivity. Some chromosomal areas can-
not be analysed reliably, e.g. repeat sequences in pericentromeric or heterochromatic 
regions, and weakly staining telomeres. Additionally, indirect labelling technique may 
cause false deletions in chromosomal areas 1p32-pter, 16p, 19, and 22 (Kallioniemi 
et al., 1994). Since CGH analysis is often complicated by normal cell contamination 
resulting in more normal DNA in the tumor sample, analysis of single cells by single 
cell comparative genomic hybridization (SCOMP) has become useful in cancer re-
search (Klein et al., 1999, Stoecklein et al., 2002). Also microarray techniques based 
on the comparative genomic hybridization (Pollack et al., 1999) have revolutioned the 
tumor biology research (see 3.3.1).  
For studies I and II, CGH was performed as described in Karenko et al., 1999. 
Briefl y, 1 µg of tumor DNA labeled with fl uorescein isothiocyanate (FITC) in a stand-
ard nick translation reaction was cohybridized with 1 µg of control DNA labeled with 
33
Texas Red (both Research Genetics). For studies III and IV, SCOMP was performed as 
described in Klein et al., 1999 and Stoecklein et al., 2002. Briefl y, microdissected and 
proteinase K-digested DNA obtained from single malignant cells was digested with Mse 
I restriction enzyme (New England BioLabs, Ipswich, MA), adaptors were ligated to the 
5’ overhangs, and DNA fragments were amplifi ed by polymerase chain reaction. The 
amplifi ed DNA was then labeled with digoxigenin-dUTP (Roche, Mannheim, Germa-
ny) and similarly processed aliquots of reference DNA obtained from peripheral blood 
mononuclear cells of healthy volunteers with biotin-dUTP (Roche). For all studies, the 
labeled probes were cohybridized with human Cot-1-DNA (Invitrogen, Carlsbad, CA) 
on normal metaphase slides in a humid chamber at 37 degrees for 2 to 3 nights. After 
posthybridization washes, the preparates were counterstained with 4,6-diamidino-2-
phenylindole (DAPI), and metaphases were viewed under a fl uorescence microscope. 
Three-color digital images were captured using an epifl uorescence microscope (Axiop-
lan imagining 2, Carl Zeiss AG, Oberkochen, Germany) equipped with a CCD camera. 
Images were analyzed with ISIS digital image analysis system (MetaSystems GmbH, 
Altlussheim, Germany) using statistical limits for green to red ratios to determine DNA 
copy number gains and losses. Eight to twelve metaphases were included in the analysis 
for each case. As an internal control, normal male and female DNA were cohybridized 
and only differences in sex chromosomes were identifi ed.
3.2.2 Fluorescence in situ hybridization, FISH (I, III–IV)
The term “in situ hybridization” generally refers to hybridization of a nucleic acid 
probe to a nucleic acid target, e.g. chromosomes in a patient tissue -derived sample 
(Gall and Pardue, 1969). Centromere-specifi c probes, representing repetitive sequenc-
es, are used for the detection of gains and losses of a specifi c whole chromosome. Gene 
deletions, amplifi cations and specifi c translocations can be studied with locus-specifc 
probes. Locus-specifi c probes, i.e. probes that recognize unique sequences normally 
present in only one copy in the haploid genome, are produced by cloning them in 
different vectors, such as cosmids, plasmids, phages, YACs (yeast artifi cial chromo-
some) and BACs (bacterial artifi cial chromosomes). Nowadays, commercial probes 
are available for several specifi c genes. FISH can be applied for metaphase chromo-
somes (metaphase-FISH) and interphase cells (interphase-FISH). The advantage of 
interphase-FISH is its usefulness for stored tissue material (Cuneo et al., 1997; Wolfe 
and Herrington, 1997), its suitability for retrospective studies as well as diagnostics 
and follow-up of clinical material. The resolution of interphase-FISH varies from 50-
200 kb to 1-2 Mb depending on the condensation level of the target chromatin (Law-
rence et al., 1990; Trask et al., 1991).
In studies I and II, touch preparates were used to produce preparates of whole 
cells. In study IV, also whole nuclei isolated from paraffi n-embedded tissue sections 
(Hyytinen et al., 1994) were used. For detection of NAV3 gene, digoxigenin-labeled 
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BACs 136F16 and 36P3 were cohybridized together with a centromere 12 -specifi c 
probe labeled with biotin. The NAV3 translocation was detected with digoxigenin-la-
beled BACs 136F16 and P36P3 with biotin-labeled BACs 786A1 and 494K17. For de-
tection of genes in chromosome 4q12, chromosome 4 copy number was determined 
with centromere-specifi c probe CEP4 (Spectrum Green, Vysis Inc., Downers Drive, 
IL), and KIT (clone RP11-586A2), PDGFRα (RP11-231C18), and VEGFR2 (RP11-
662M13) copy numbers using BAC probes (Invitrogen Ltd., Paisley, U.K.) (Joensuu et 
al., 2005). All probes were labeled with nick translation, hybridized in a humid cham-
ber for 2–3 nights and detected with anti-digoxigenin rhodamine or avidin-FITC 
depending on the primary fl uorochrome. After post-hybridization washes, slides 
were counterstained with 0.1 µmol/L 4,6-diaminido-2-phehylindole in an antifade 
solution and viewed under a fl uorescence microscope equipped with an ISIS digital 
image analysis system (MetaSystems, Altlussheim, Germany). Signal copy numbers 
were counted from 50 to 100 randomly chosen non-overlapping interphase nuclei. A 
nucleus with an equal number of fl uorescence signals from the centromere probe and 
the BAC probes was considered normal. Amplifi cation is manifested as a nucleus with 
a higher number of signals from the BAC than from the centromere areas, whereas in 
a deletion the number of centromere signals exceeds the number of BAC signals. The 
analyses were done blinded to the diagnosis or sample identity. The highest percent-
age of cells with aberrant signal patterns observed in reference samples was consid-
ered as cutoff level. 
3.2.3 Multicolor fl uorescence in situ hybridization
(I–II, unpublished)
Multicolor FISH by staining each chromosome with a specifi c color combination re-
veals the origins of marker chromosomes detected by less sensitive methods, and more 
importantly reveals structural chromosomal aberrations, even the balanced translo-
cations, not demonstrable with other hybridization techniques (Nederlof et al., 1990, 
Dauwerse et al., 1992, Ried et al., 1992). However, intrachromosomal aberrations, like 
inversions, deletions and amplifi cations of small chromosomal areas are diffi cult to 
observe. Multicolor-FISH utilizes two different technologies in fl uorescent detection: 
multifl uor FISH (MFISH), where the imaging is performed separately for each six 
colors (Speicher et al., 1996) and spectral karyotyping (SKY), where only one image 
is necessary and the analysis utilizes Fourier transformation (Schröck et al., 1996). In 
this study patient-derived PHA-stimulated peripheral blood lymphocytes were cul-
tured for three days for conventional metaphase spreads. The 24-color probe mixture 
(24XCyte-MetaSystems’ 24 color kit, MetaSystems GmbH, Altlussheim, Germany) 
and the metaphase slides were denatured, and hybridization was performed in a hu-
mid chamber for 4-6 days. After posthybridization washes, the biotin labeled probes 
were detected with streptavidin-Cy5 and the preparations were mounted in antifade 
35
and 4,6-diamidino-2-phenylindole (DAPI, B-tect kit MetaSystems GmbH) according 
to the manufacturer’s instructions. Digital images of the metaphases were taken with 
an epifl uorescence microscope (Axioplan imaging 2, Zeiss, Germany) equipped with 
a CCD camera, and analyzed with ISIS digital image analysis system (MetaSystems). 
The number of metaphases analyzed for each case ranged from 30 to 75 depending on 
the availability of representative metaphases.
3.3 Microarrays
Gene-level aberrations characterizing CTCL and providing new pathomechanistic in-
sights, diagnostic, therapeutic and follow-up tools, are studied by microarray technol-
ogy. The main purposes for microarray technology are gene expression analysis and 
gene copy number analysis. Additionally, other microarray technologies, e.g. single 
nucleotide polymorphism (SNP) arrays, and chromatin immunoprecipitation-on-a-
chip (ChIP-on-chip) arrays exist. To date, several microarray platforms are available. 
In this thesis, gene expression analysis on oligonucleotide microarrays (Affymetrix) 
and gene copy number analysis on custom-made cDNA arrays was performed. 
3.3.1 Array-based comparative genomic hybridization 
(unpublished data)
The array-CGH method is based on simultaneous hybridization of differentially la-
belled tumor and normal DNA on microarrays that contain short fragments of DNA 
as probes. CGH microarrays can be composed of genomic clones (e.g. BACs), cDNA 
clones, or short oligonucleotide sequences spotted on a glass slide by a robotic arrayer 
or synthesized in situ. Compared to chromosomal CGH (see 3.2.1), the main ad-
vantage of the array technology is the signifi cantly improved resolution allowing the 
analysis of single gene copy number aberrations across the whole genome. Another 
advantage is that one can study both the expression and copy number on an identical 
array.
In this study, CGH microarray was performed using custom-made arrays conta-
ing 32,000 cDNA clones representing approximately 16,000 genes in duplicates. Hy-
bridizations were performed as previously described (Pollack et al., 1999; Monni et 
al., 2001). Briefl y, 2 µg of tumour cell DNA was labelled with Cy5-dUTP (Amersham 
Pharmacia Biotech) and similarly processed gender-matched reference DNA with 
Cy3-dUTP (Amersham Pharmacia Biotech) by random priming using a BioPrime 
DNA labeling system kit (Invitrogen). After hybridization over night at 65 °C and 
post-hybridization washes, the slides were scanned using Agilent laser confocal scan-
ner (Agilent Technologies, Palo Alto, CA), and the results were analyzed using Agilent 
Feature Extraction Software 8.1. Additionally, two normal versus normal hybridiza-
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tions were performed (one self versus self and one sex-mismatch) in order to identify 
variation that is due to technical aspects. DNA copy number ratios were calculated 
by dividing the background corrected red fl uorescence intensity representing the test 
hybridization signal by the background corrected green fl uorescence intensity repre-
senting the control hybridization signal. Logarithms of the fl uorescent ratios (log2 
values) were used for the analysis. Within slide normalization for each array was per-
formed using Lowess method. After within slide normalization, the data was fi ltered 
to eliminate low quality measurements. Filtering was performed in GeneSpring by 
eliminating features that were fl agged as saturated or for which the distribution of 
signal and background pixels were fl agged as non-uniform or as population outliers 
by the fl ag outliers algorithm adopted in the Feature Extraction software. Mapping of 
genes to the clones present on the arrays was performed using software developed at 
the Biomedicum Bioinformatics Unit (University of Helsinki, Finland). In brief, the 
software followed a procedure in which nucleotide sequences for all the clones spotted 
onto the array were retrieved from GenBank and blasted against the most recent ver-
sion of the human genome assembly. The blasting algorithm employed was optimised 
with regards to window size and how to handle multiple hits, allowing the fl agging of 
clones whose physical location was ambiguous so that they could be excluded from 
further analysis. Unambiguous information was available for 13,383 clones represent-
ing an average resolution of 187.5 kilobases throughout the genome. The CGH copy 
number data were ordered according to the location of clones along chromosomes. 
Genes with copy number ratio exceeding the value 1.32 (log2 0.4) were regarded as 
amplifi ed, whereas genes with copy number ratio less than 0.76 (log2 –0.4) were con-
sidered deleted. The limits were defi ned based on the variation of copy number sig-
nals in normal versus normal hybridizations. In self versus self hybridization, 95.7% 
of the clones represented on the array, are inside these limits. Based on the fact that 
amplicons usually span larger regions of the genome rather than a single gene, four or 
more adjacent clones were required to show a copy number ratio exceeding 1.32. The 
same criteria were used to determine the deleted areas. 
3.3.2 Gene expression microarrays (II)
Gene expression analysis can be performed using either cDNA or oligonucleotide 
microarrays. The principle of the technique is to compare the relative abundance 
of expressed sequences in two RNA samples (test and similarly processed reference) 
(Golub et al., 1999; Singh et al., 2002). The expression of tens of thousands of genes 
can be measured in a single experiment (Lockhart et al., 1996; Wodicka et al., 1997). 
Various commercial array platforms are available at the moment, e.g. from Affymerix, 
Agilent, or Illumina bead array chips. Each Affymetrix array contains several thou-
sand genes or ESTs (expressed sequence tag) with 8-16 oligonucleotide sequences 
chosen to represent each gene. With specifi c optimized protocols for small samples, 
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the amount of starting material may be as little as 100 ng of purifi ed RNA. The bead 
array technology of Illumina is based on molecules in the sample binding to their 
matching molecules on the coated bead. 
In this study, Affymetrix oligonucleotide array HG-U133A was used. The quality 
of RNA samples was confi rmed with gel electrophoresis and samples were prepared 
for hybridization according to Affymetrix small sample protocol (Affymetrix Techni-
cal note, GeneChip Eucaryotic Small Sample Target Labelling Assay Version II). Start-
ing material for the synthesis was 100 ng of total purifi ed RNA (RNeasy Mini, Qia-
gen, Valencia, CA). Labeled and fragmented cDNA was hybridized against Affymetrix 
HG-U133A chip  (Affymetrix, Santa Clara, CA) containing probes for over 22 000 
transcripts. 
Gene expression data were GC-RMA –normalized and log-transformed (Wu et 
al., 2004; www.bioconductor.org). Gene expression levels of each patient were com-
pared to the average of the controls to obtain a patient-specifi c expression profi le. 
Genes that were differentially expressed between the patient and the control groups 
were identifi ed by the modifi ed t-test (Smyth, 2004). A gene was considered changed 
if the p-value of the test was less than 0.05 and there was at least a 2-fold change in the 
mean expression levels. The statistical analyses were carried out with R (http://cran.
r-project.org) packages Affy and Limma. The expression results were visualized with 
the TreeView software (Eisen et al., 1998).
3.3.3 Correlating gene expression microarray data with 
CGH data (II)
Patient-specifi c gene expression profi les were constructed by calculating gene expres-
sion ratios between each patient and the average of the matched controls. Microarray 
probe sets were mapped along the chromosomes using the Bioconductor annotation 
package hgu133a to assess regional biases in the expression profi les. If multiple probe 
sets mapped to the same locus, the average of their expression values was used in the 
analysis. To identify chromosomal regions with upward or downward expression bias, 
the sign test proposed by Crawley and Furge (2002) was applied to each cytoband. 
The sign test scores a gene as up- or down-regulated if the expression change is at 
least 1.8-fold, and determines whether the corresponding chromosomal arm contains 
a statistically signifi cant number of genes that change in the same relative direction. 
The DNA copy number gain and loss regions were identifi ed from the chromo-
somal CGH data by using MetaSystems ISIS software (see 3.2.1). When comparing 
the CGH data with the chromosomal regions (arms) showing gene expression biases 
by sign test, chromosomal arms with gene copy number and gene expression chang-
ing to the same direction, were identifi ed.
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3.4 Confi rmation of gene expression in tissue samples
In addition to the microarray technology, expression levels of certain specifi c genes or 
proteins, were analysed by real-time quantitative PCR, and immunohistochemistry.
3.4.1 Real-time quantitative PCR (I–II)
Real-time quantitative PCR is a method to monitor the progress of the PCR as it oc-
curs (i.e., in real time). At fi rst, complementary DNA (cDNA) is produced from total 
RNA extracted from the samples. Then, a PCR is performed during which the accu-
mulation of the PCR product is assessed in real time. PCR reactions are performed 
by using specifi c probes or dyes, and the amount of the PCR products of the gene of 
interest in relation to the reference gene are measured by standard curve method or 
comparative C
t
 method (see below). 
In SYBR Green I Dye technology, SYBR Green I dye detects PCR products by bind-
ing to all double-stranded DNA formed during PCR, and no probe is required. The Taq-
Man technology, instead, is based on the usage of a fl uorogenic probe, which consists of 
an oligonucleotide with a reporter and quencher fl uorescent dye attached. During PCR, 
if the target of interest is present, the probe anneals specifi cally between the forward 
and reverse primer sites. Taq DNA polymerase cleaves the probe during the PCR with 
its 5’-3’ exonuclease activity, if the probe hybridizes with the target sequence (Holland 
et al., 1991). The cleavage separates the reporter dye from the quencher and therefore 
increases the reporter dye fl uorescence signal (Lee et al., 1993). The progress of the PCR 
can be monitored in real time as the accumulating intensity of the reporter dye (Mul-
lah et al., 1998). The parameter C
t 
(threshold cycle) is used to measure the number of 
amplifi cation cycles required to detect a signal, and it is defi ned as the number of PCR 
cycles required for the detection of fl uorescent signal to exceed a fi xed threshold
To analyse NAV3 expression (Study I) or to confi rm the microarray gene expres-
sion data (Study II), real-time quantitative PCR was performed. The cDNA was pre-
pared with Revert Aid TM First Strand cDNA Synthesis Kit (Fermentas, St.Leon-Rot, 
Germany; Study I) or with Superscript II kit (Gibco BRL, Life Technologies, Paisley, 
Scotland; Study II). PCR reactions were performed in LightCycler TM apparatus using 
an LC Fast Start DNA SYBR Green 1 kit (Roche Diagnostics, Mannheim, Germany) 
followed by melting curve analysis according to the manufacturer’s guidelines (Wit-
twer et al., 1997; Study I) or the PCR reactions were carried out using ABsolute QPCR 
ROX mix (ABgene, Epsom, UK) with 300 nM primers and 200 nM probe followed by 
detection Applied Biosystems’ ABI Prism 7700 sequence detector (Study II). Primer 
and probe sequences are listed in Table 4. Linearity of amplifi cation was confi rmed by 
running standard curves for each amplicon and specifi city of the reagents was verifi ed 
by gel electrophoresis. The results were normalized against TBP (Study I, Linja et al., 
2004) or EF1α (Study II, Hämäläinen et al., 2001) detection value. 
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Table 4. Real-time quantitative PCR reagents
Probe ID Target gene 1) 5' -F primer - 3' 
2) 5' -R primer - 3' 
3) 5' -Probe - 3' 
NAV3 1) ATCCATGGAGCTCAGCAACTC
2) TGGCTGCTTCTTGGAGTTT






205291_at IL2Rb 1) CCCAATACAAAAATACCTACTGCTG
2) TTTGGATATAAAGGCAACAGGAA
3) ProbeLibrary Human#66






215838_at LIR9 1) TCCTGCAGGTATGGTCAGAA
2) ACTGAGGTTATCAGCTGCTCCT
3) ProbLlibrary Human#79
203936_s_at MMP-9 1) GTGCCATGTAAATCCCCACT
2) TTTGTATCCGGCAAACTGG
3) ProbeLibrary Human#60
213915_at NKG7 1) TCCCTGGGCCTGATGTTCT
2) TGGGACCCACAGCCTCAA
3) CCTGATTGCTTTGAGCACCGATTTCTG
204351_at S100P 1) CCGTGGATAAATTGCTCAAGGA
2) CATTTGAGTCCTGCCTTCTCAAA
3) TTCGTGGCTGCAATCACGTCTGC
204655_at SCYA5 1) TCCCGAACCCATTTCTTCTCT
2) CCCAGCAGTCGTCTTTGTCA
3) TTGGCACACACTTGGCGGTTCTTTC
204466_s_at SNCA 1) TGTTCCATCCTGTACAAGTGCT
2) CGAGATACACTGTAAAAACTTTGAGAA
3)  ProbeLibrary Mouse#80
220684_at TBX21 1) ACAGCTATGAGGCTGAGTTTCGA
2) GGCCTCGGTAGTAGGACATGGT
3) TCAGCATGAAGCCTGCATTCTTGCC





Immunostainings for CD52 (source and dilution for all antibodies are given in Table 
5), IL7R, IL7, and KLK10 were performed with Vectastain Elite Mouse kit (Vector 
Laboratories, Burlingame, California) on frozen tissue sections, according to manu-
facturer’s instructions. MMP-9 immunostaining was performed on formalin-fi xed 
paraffi n-embedded tissue sections using a mouse monoclonal antihuman MMP-9 
antibody as previously described (Saarialho-Kere et al., 1993). For study III, sections 
cut from the paraffi n-embedded biopsies were immunostained for membrane anti-
gens CD3, CD4, CD5, CD7, CD8, CD30, CD56, Granzyme B, TIA1, Ki-67, and TCR 
alpha/beta according to manufacturers’ instructions and visualized with DakoEnvi-
sion (Glostrup, Denmark). KIT expression was demonstrated with a rabbit polyclonal 
anti-CD117 antibody, as described in detail elsewhere (Sihto et al., 2007). The bind-
ing of the primary antibody was detected with a Powervision+ Poly-HRP histostain-
ing kit (DPVB+110DAB, Immunovision Technologies Co, Daly City, CA). All tissue
sections were counterstained with hematoxylin. The stainings were graded as negative 
(-), weakly positive (+; less than 10% of tumor cells expressed the protein), moder-
ately positive (++; 10 to 50% of tumor cells were positive) or strongly positive (+++; 
over 50% of the tumor cells expressed the protein). 
Table 5. Antibodies used in immunohistochemistry
Antibody Source Dilution Study
CD52 Abcam, Cambridge, UK  1:100 II
IL7R R&D Systems, MN, USA  1:10 II
IL7 R&D Systems, MN, USA  1:20 II
KLK10 R&D Systems, MN, USA  1:30 II
MMP-9 Diagnostics Inc, Flanders, New Jersey  1:50 II
CD3 Novocastra, New Castle, UK  1:100 III
CD4 Novocastra, New Castle, UK  1:150 III
CD5 Novocastra, New Castle, UK  1:25 III
CD7 Novocastra, New Castle, UK  1:100 III
CD8 Novocastra, New Castle, UK  1:25 III
CD30 Dako, Glostrup, Denmark  1:25 III
CD56 Zymed, South San Fransisco, CA  1:50 III
Granzyme B Monosan, Uden, The Netherlands  1:100 III
TIA-1 Biocare, Birmingham, UK  1:200 III
Ki-67 / MIBI Dako, Glostrup, Denmark  1:50 III
TCR alpha / beta GeneTex, TX, USA  1:100 III
KIT = CD117 Dako, Glostrup, Denmark  1:300 IV
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3.5 Other methods
3.5.1 Loss of heterozygosity analysis (III–IV)
Loss of heterozygosity (LOH), also called allelic imbalance, can be measured by com-
paring the amount of PCR products amplifi ed from the two constitutional chromo-
somes. This is possible when the sequence amplifi ed contains a polymorphism that 
distinguishes between the two alleles. Typically, the polymorphic sequences that are 
utilised for LOH mapping are microsatellite repeats. Microsatellites are short tandem 
repeats of very simple DNA sequences, usually 1–4 bp long, for example (GT)
n
, that are 
widely dispersed throughout the genome. 
LOH analysis by microsatellite markers was performed to reveal the allelic loss 
of NAV3 or confi rm the NAV3 deletion detected by interphase-FISH. For NAV3 LOH 
analysis we chose three microsatellite markers spanning the NAV3 gene locus at 
12q21.2–q21.31 and surrounding the gene from both directions (Figure 3). The PCR 
amplifi cation primers are shown in Table 6. The forward primers were fl uorescently 
labeled with FAM and PCR fragments were run on the ABI3730 sequencer/genotyper 
and the results were analysed using GeneMapper v3 software (Applied Biosystems, 
Europe). A sample was scored as showing LOH, if one of the alleles in the tumor 
sample had decreased 40% or more compared to its matching normal and decrease of 
21–39% of one allele relative to the other allele (in tumor tissue compared to match-
ing normal tissue) is termed putative LOH. (Canzian et al., 1996).
Table 6. Microsatellite markers used for NAV3 LOH analysis
Marker Distance from NAV3 1) 5' - F primer - 3'
2) 5' - R primer - 3'
D12S1684 1.0 Mb 1) CCTGCATGCCTCAGTTATGA
2) AACAAGCCATACCAGTCAGG
D12S326 0.2 Mb 1) ACCAGGCTCCCCTAAAAGTG
2) AGAATGACCAGACCCACAGG
D12S1708 3.8 Mb 1) GGGAACTTATGTCAAGGCTAGGA
2) GATCTAGTGCTCAAGAGGTTTTCAA
Figure 3. NAV3 gene in relation to the microsatellite markers used in studies III–IV.
Drawn according to ideas of Dr. Ulla Aapola, Dermagene Oy.
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3.5.2 Gene silencing by RNA interference technology (I)
RNA interference (RNAi) is a mechanism for RNA-guided regulation of gene expres-
sion in which double-stranded ribonucleic acid inhibits the expression of genes with 
complementary nucleotide sequences. RNAi technique was used to silence the gene 
producing NAV3-protein in human lymphoid cell lines and thus, mimicking the situ-
ation in vivo in CTCL. NAV3 gene silencing was performed with small interfering 
RNA-expressing lentivirus constructs. Several DNA sequences encoding small inter-
fering RNA (siRNA) precursors based on the NAV3 sequence were cloned in the lenti-
viral vector pLL3.7 for expression under the U6 promoter, including GFP expression, 
and the most specifi c inhibition was observed with a 23-nucleotide sequence from the 
NAV3 exon 19. This derivative was then used for production of infectious short hair-
pin RNA–expressing lentiviruses as described in more detail in Study I. The number 
of infected cells (GFP-positive) were estimated by fl uorescence-activated cell sorting 
(FACS). The NAV3 expression of FACS-sorted (BD FACSAria; BD Biosciences) GFP-
positive cells was studied with quantitative RT-PCR by Light Cycler device (Roche 
Diagnostics, Mannheim, Germany), as described in 4.4.1.
3.5.3 Additional methods
The most important methods for this thesis are presented above. Other methods that 
have been used, include immunofl uorescence, Western blot, DNA sequencing, de-
naturing high-performance liquid chromatography (DHPLC), reverse transcriptase 
PCR / conventional PCR, and fl ow cytometry analyses. These methods are described 
in more detail in Study I.
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4. RESULTS AND DISCUSSION
4.1 Chromosomal aberrations characterizing different 
CTCL subtypes (I–IV)
4.1.1 Combination of molecular cytogenetics and gene 
expression profi ling reveals chromosomal regions with both 
gene expression and DNA copy number changes (II)
It has been shown previously, that at least 12% of the differences seen at transcrip-
tional level are due to the variation in gene copy number (Pollack et al., 2002). To 
reveal the impact of gene copy number on gene expression among CTCL patient se-
ries, an integrated analysis of CGH and microarray-based gene expression profi ling 
on 4 SS PBMC and 3 MF skin samples was performed. By gene expression analysis, 
a signifi cant, consistent upward bias in gene expression levels was found in at least 
four of the seven patient samples in the following fi ve chromosome arms: 1q, 3p, 3q, 
16p, and 16q. In addition, chromosome arms 4q and 12q, exhibited both an upward 
and a downward bias (Study II, Figure 4a). To integrate the chromosomal and tran-
scriptomic data, these chromosomal regions were compared with the CGH data. In 
three of the above seven chromosomal arms, 1q, 4q, and 16q, with an upward bias, a 
signifi cant gain was detected also in CGH in at least four of the seven MF skin or SS 
blood samples. A signifi cant gain was detected in at least two of the samples in chro-
mosomes 3p, 3q, and 12q and in one sample in chromosome 16p. In chromosomes 4q 
and 12q, where also downward expression bias was identifi ed, a loss was detected by 
CGH in one and two of the samples, respectively.  (Study II, Figure 4c.)
In CTCL, gains of chromosome arms 1q, 3p, 3q, 4q, and 16q have been observed 
previously by CGH (Karenko and Kähkönen, unpublished observation) and diverse 
aberrations of these chromosomes are common by other cytogenetic or molecular cy-
togenetic methods (Karenko et al., 1997; Mao et al., 2002). These chromosome arms 
contained altogether 23 and 30 probe sets found to be upregulated in SS patients’ 
PBMC samples and MF patients’ skin samples, respectively, which represent 0.7 and 
1.0 percent of all array probe sets included in these chromosome arms. For example, 
the upregulated SNCA gene (see 5.3.2) locates to cytoband 4q21. The above chromo-
some arms, thus, are potential targets for searching for further recurring gene aber-
rations in CTCL.
44
4.1.2 Chromosomal aberrations characterizing SPTL and 
differentiating SPTL from the other CTCL subtypes 
(III, unpublished)
Of the rare subtypes of CTCL, i.e. other than MF and SS, SPTL was studied because 
of its different clinical picture (see 1.2.1.3), and more importantly because of its dif-
fi cult clinical diagnosis. Chromosomal and genomic analysis was performed in order 
to achieve some more knowledge about the poorly known mechanisms of this disease 
entity. 
To ensure the best possible representativeness of the sample material where malig-
nant cells are sparse and scattered among other normal cells of the skin, the morpho-
logically malignant cells were collected by single-cell laser microdissection. The pure 
malignant cell population thus obtained, showed several novel DNA copy number 
abnormalities by CGH. The DNA copy number changes were very uniform between 
individual patients with a large number of changes occurring in the vast majority of 
the cases. The most common CGH fi ndings were DNA copy number losses in chro-
mosomes 1p (6/6 cases), 2p (5/6), 2q (4/6), 5p (5/6), 7p (4/6), 9q (5/6), 10q (5/6), 11q 
(5/6), 12q (5/6), 16 (5/6), 17q (4/6), 19 (4/6), 20 (6/6), 22 (6/6), and gains in chromo-
somes 2q (5/6), 4q (5/6), 5q (4/6), 6q (4/6), and 13q (4/6) (Study III, Figure 2).
Previous CGH studies on MF and SS have demonstrated gains in chromosomes 2q 
(Mao et al., 2002; Karenko et al., 1999) and 4q (Mao et al., 2002; Study II). As described 
above (4.1.1), chromosome arm 4q is also among the areas with the highest frequency 
of upregulated genes among the more common CTCL subtypes (Study II). Chromo-
somal losses of 1p, 17p, 10q, and 19 were the most common CGH changes in a British 
study of 34 CTCL patients (Mao et al., 2002), and other groups have demonstrated 
losses of 10q and 17p to be the key aberrations in CTCL (Karenko et al., 1999; Fischer 
et al., 2004). On the other hand, losses of chromosomes 5q and 13q occur in the most 
common forms of CTCL (Karenko et al., 1999; Fischer et al., 2004), but in SPTL these 
areas showed DNA copy number gains by CGH. The current fi nding of losses in chro-
mosome 12q in most cases of SPTL is in concordance with our previous identifi cation 
of both DNA copy number loss and a downward gene expression bias in chromosome 
12q observed in Study II. It may be speculated that aberrations in chromosome arms 
common to both SPTL and MF/SS, may not infl uence the prognosis, since the progno-
sis of SPTL is favourable and that of SS less favourable. It has previously been observed 
that 17p loss and 7 gain do not infl uence the prognosis of CTCL (MF and SS) patients 
(Fischer et al., 2004). Instead, 13q loss has been found to associate with shorter survival 
among MF and SS patients (Fischer et al., 2004), and interestingly, SPTL patients did 
not show this abnormality, but instead, frequently had a gain at 13q. 
Although the malignant cells of the subcutaneous SPTL lesions showed a large 
number of genomic changes, clonal aberrations in blood lymphocytes could be iden-
tifi ed by MFISH in only one case. The neoplastic cell clones, thus, seem mainly to 
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be restricted to the subcutaneous tissue. This fi nding is in line with the recently re-
vealed favourable clinical prognosis of SPTL with TCR α/β positive T-cell phenotype 
(Willemze et al., 2005; Willemze et al., 2008), and further encourages introduction 
of less potentially hazardous treatment modalities than multi-agent chemotherapy. 
Interestingly, one case had three different clones in blood by MFISH [dup(16)(q?q?), 
del(11)(q?), and del(13)(q?)], one of which was also identifi ed in the subcutaneous 
tissue by CGH, whereas the two others were not. This suggests the presence of differ-
ent clones or subclones in the skin and blood, which has been observed in other CTCL 
forms as well (Muche et al., 2004).
The array-CGH performed on microdissected skin samples amplifi ed with the 
whole genome amplifi cation method resulting in DNA fragments of 256 bp of length 
in average, was not technically successful. On the contrary, array-CGH of one case 
(the one with changes in MFISH) on peripheral blood DNA sample isolated with 
standard methods demonstrated frequent DNA copy number aberrations in chro-
mosomes 1, 2, 5, 7, 11, 17, and 19. These aberrations were only partly overlapping 
with those characteristic for the malignant subcutaneous T-lymphocytes as defi ned 
by CGH, further pointing to the existence of different subclones in skin and blood.
4.1.3 CTCL-associated lung cancers show chromosomal 
aberrations differing from primary lung cancer and resembling 
aberrations observed in CTCL primary lesions (skin/blood) (IV)
Since CTCL and lung cancer share some chromosomal aberrations (see 1.2.4.1), 
eventual chromosomal and genomic similarities and differencies in lung cancers de-
veloped in CTCL patients and in solitary lung cancers were searched. Comparative 
genomic hybridization on fi ve CTCL-associated secondary lung cancer cases and on 
fi ve reference cases with primary lung cancer was performed. The most common DNA 
copy number aberrations in both groups are illustrated in Figure 4. The reliability of 
the microdissection-based method was confi rmed by the fact that DNA copy number 
aberrations in reference lung cancer without CTCL-association were in concordance 
with those reported in the literature. These results revealed that CTCL-associated lung 
cancer differs from primary lung cancer for the DNA copy number changes. CTCL-
associated lung cancers showed some of the typical lung cancer aberrations, e.g. losses 
of 5q, 10q, and 16q, as well as gains of 3q, and 5p, but also aberrations that are not 
frequent primary lung cancer, like gains of 4q gain 9p. Additionally, some of the DNA 
copy number changes found in CTCL-associated lung cancer (both SCLC and NSCLC) 
are frequent in CTCL, e.g. losses of 1p and 10q, and gains of 4q, 7, and 8q, which were 
present in at least 3/5 of the CTCL-associated lung cancer samples and losses of 13q, 
17p, and 19, as well as 18 gain, which were present in fewer samples. The changes 
common to both CTCL and lung cancer were loss of 10q, 13q and 17p, and gains of 
7 and 8q (Coe et al., 2006; Garnis et al., 2006). Additionally, in CTCL-associated lung 
46
cancer, some aberrations frequent in primary / reference lung cancer, were rare, if any 
(detected in maximum one of the fi ve cases), especially 4q loss, 8p loss, and 19q gain. 
(Study IV, Figure 1a.) Typically, deletions of 4q have been considered as hallmark of 
lung cancer, especially for small cell lung cancer (Balsara and Testa, 2002), but in CTCL 
4q belongs to the most frequently amplifi ed (Mao et al., 2002) as well as overexpressed 
chromosomal regions (Study II). Three of the fi ve CTCL-associated secondary lung 
cancer cases showed gains in 4q, and only one showed losses. Taken together, CGH 
revealed CTCL-associated lung cancers to harbour chromosomal aberrations differing 
from primary lung cancer, especially losses of 1p and 19, and gains of 4q and 7.
Figure 4. The main differences between CTCL-associated and reference lung cancer.
X-axis illustrates the chromosome arms, whereas Y-axis depicts the percentages of gains 
(positive percentages, above the central line) and losses (negative percentages, below the 
central line) identifi ed for CTCL-associated lung cancer (black bars) and reference lung 
cancer (grey bars). Original fi gure from Study IV, supplementary data.
4.2 Gene expression profi ling of CTCL (II)
A total of 17 samples from 9 patients and 14 samples from 9 controls were successfully 
hybridized on Affymetrix gene expression microarrays. To mask the effect of infi ltrating 
non-malignant, reactive T cells on CTCL-associated gene expression profi ling, com-
monly present in the samples of CTCL (Wood et al., 1994; Bagot et al., 1998; Berger 
et al., 2005), comparison of microarray data from different cell populations of CTCL 
patients was performed, and changes common to different cell sources of MF patients 






















































Altogether 168 probe sets (fold change > 2, p-value < 0.05; representing approxi-
mately 0.8 percent of all the probe sets included in the array) were differentially regu-
lated in Sezary syndrome PBMC samples compared to control PBMC samples. Of 
these genes, the majority was upregulated. Comparable amount of differences was 
also found between MF blood CD4+ and control blood CD4+ samples (205 probe 
sets, 0.9%). As expected, fewer differences, only 40 differentially regulated probe sets 
(0.4%), were found in MF PBMC samples. Instead, there were substantial differences 
in gene expression when MF skin samples were compared to control skin samples 
from patients with infl ammatory dermatoses (223 probe sets, 1.0%), and most of the 
differences were due to the increased gene expression. The gene expression changes 
found in different cell types are shown in Figure 5. Because the number of malig-
nant cells in Sezary syndrome patient blood samples is considerably greater than that 
in mycosis fungoides patient blood samples, the gene expression profi les varied re-
markably between Sezary syndrome and mycosis fungoides PBMC samples (Study 
II, Figure 1E). However, a subset of genes was found to change in a similar manner in 
both Sezary syndrome and mycosis fungoides PBMC samples (Study II, Figure 1F and 
Table 1). Among these similarly regulated genes, are e.g. CD160 downregulation, and 
upregulation of LIR9, STAT1, SNCA, MMP-9, and S100P. SNCA and LIR9 genes were 
upregulated both in SS and MF patients’ PBMC samples, and MF skin biopsies and 
MF CD4+ cells, respectively. Commonly upregulated genes in the cell populations 
representing the primary or most frequent site of malignant cells (SS PBMC and MF 
skin) included e.g. ITM2A, ETHE1, and BARD1.
In Sezary syndrome samples, two Th1-specifi c genes (SCYA5 and NKG7) and IL-
2Rβ, VAV3, DLG5, and KIR3DL2 were found to be >2-fold down-regulated. Genes 
upregulated in both mycosis fungoides and Sezary syndrome blood samples included 
S100P and MMP-9. In lesional mycosis fungoides skin samples compared with in-
fl ammatory dermatoses, IL-7R and CD52 were up-regulated. SNCA and LIR9 genes 
were up-regulated in several cell populations of Sezary syndrome and mycosis fun-
goides patients. These genes were selected for further analysis by quantitative PCR and 
immunohistochemistry, in addition to the TBX21 (T-bet) gene, based on its crucial 
role in Th1 differentiation (Szabo et al., 2000). The selection of the genes for further 
analysis was not only based on fulfi lling the statistical and biological criteria for dif-
ferent regulation in microarray analysis (p < 0.05 and fold change > 2) but also on the 
presumed impact of a certain gene on CTCL pathogenesis. (Study II, Figures 1A-D)
QPCR done on 11 selected genes (T-bet, SCYA5, NKG7, IL-2Rβ, VAV3, DLG5, 
KIR3DL2, S100P, MMP-9, SNCA, and LIR9; Study II, Figure 2) and immunohisto-
chemistry performed on 4 gene products (CD52, IL-7R, IL-7, and MMP-9; Study 
II, Figure 3) validated the microarray data. In general, the changes in the expression 
levels of the selected genes, demonstrated even more pronounced when measured 
with QPCR compared to microarrays. Eleven additional CTCL patient samples and 7 
additional control samples were included in the QPCR and IHC analyses.
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To conclude, these fi ndings provide the basis for the previously observed Th2-
type cytokine-profi le for Sezary syndrome, because a set of Th1-specifi c genes was 
downregulated in Sezary syndrome samples. Moreover, the different biology behind 
MF and SS was demonstrated by different gene expression signatures of these com-
mon CTCL subtypes (Study II, Figure 1E). 
Figure 5. Substantial differences in gene expression profi les were found in SS PBMC, 
MF CD4+ and skin biopsy samples, compared to corresponding control samples. The 
most differentially (p<0.05 and fold change>3) expressed genes between patient and con-
trol samples are shown: SS PBMC (A), MF skin biopsies (B), MF CD4+ cells (C) and MF 
PBMC (D). Original picture in Study II, supplementary data.
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4.3 Novel target genes characterizing different CTCL 
subtypes (I–IV)
4.3.1 NAV3 gene deletion is frequent in many CTCL sybtypes 
and happens already at the early stages (I, III, IV)
In search for recurrent chromosomal aberrations in the most common forms of 
CTCL, structural chromosome aberrations, as defi ned by MFISH, were found most 
frequently in chromosome 12 (in 6/7 SS patients). In one of these patients, a balanced, 
clonal translocation t(12;18)(q21;q21) was identifi ed and lead to the identifi cation of 
the gene involved in the translocation. When minimizing the common area of dele-
tion in the above cases, signal division in FISH analyses of metaphase chromosomes 
indicated that the translocation break point lies within BAC probes RP11-494K17 
and 36F16, which both contain parts of the NAV3 gene, thus disrupted by the translo-
cation (Study I, Figure 2). The NAV3 gene, also named POMFIL1, locates to chromo-
some band 12q21, and losses of one copy of its distal part in relation to chromosome 
12 centromere was found in 4/8 early stage (MF IA-IIA) and 11/13 advanced stage 
CTCL patients (MF IIB-IV or SS) as studied with locus-specifi c FISH on touch pre-
parates of skin lesions (Study I, Figure 4). Allelic loss of NAV3 was also demonstrated 
in more rare CTCL subtypes, namely SPTL, in which it was found in 2 of 3 patients 
with FISH and in 4 of 4 patients by the LOH technique (Study III). Of the blood 
lymphocyte DNA from the seven SS cases, six with a cytogenetic aberration of 12q, 
studied with DNA sequencing or DHPLC, only one showed a missense mutation in 
the microscopically intact allele of NAV3. 
Allelic loss of NAV3 was also studied in CTCL-associated lung cancer by LOH 
technique. However, the CTCL-associated lung cancer cases were uninformative due 
to constitutional homozygosity and/or suboptimal performance in the LOH assays. 
Instead, all fi ve reference lung cancer cases were successfully analyzed, and loss of het-
erozygosity for NAV3 was found in two of the four informative cases. One sample was 
uninformative for all three LOH markers used. (Study IV, Figure 4)
NAV3 is a large gene, consisting of 40 exons and spanning around 400 kb of ge-
nomic sequence. The function of NAV3 is largely unknown. It is one of three human 
homologues of UNC-53, involved in axon guidance in C. Elegans, and it has predictive 
properties of a signal transduction protein and actin interactions. (Coy et al., 2002; 
Ishiguro et al., 2002; Maes et al., 2002; Merrill et al., 2002; Stringham et al., 2002). 
By structure it is also a helicase and an exonuclease with similarity to proteins caus-
ing Werner’s and Bloom’s syndromes and with the role of maintaining chromosomal 
stability (Coy et al., 2002; Maes et al.; 2002; Ishiguro et al., 2002; Nakayama, 2002). 
By its location in the nuclear membrane, NAV3 might also affect nuclear transport 
or kinetochore formation and cell cycle control (Maes et al., 2002; Coy et al., 2002; 
Fahrenkrog and Aebi 2003). Deletions or lowered expression of NAV3 has been found 
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in neuroblastoma, too (Coy et al., 2002). By RT-PCR, NAV3 expression was found 
only in PHA-stimulated but not in resting human lymphocytes (Study I). Moreo-
ver, NAV3-siRNA silenced Jurkat cells and peripheral blood lymphocytes showed in-
creased IL-2 production (Study I, Figure 6). Based on these functional consequences 
of NAV3 allelic loss, and the fact that point mutations in the remaining NAV3 allele 
were only rarely observed, NAV3 is believed to function as a haploinsuffi cient tumor 
suppressor gene. Further characterization on the effects of NAV3 loss in different hu-
man cells and tissues as well as in an animal model is in progress.
4.3.2 Th1 response and cytotoxicity genes are downregulated 
in SS and MF (II)
Of the Th1-specifi c genes down-regulated in Sezary syndrome, TBX21 (T-bet) and 
TXK represent transcription factors essential for T helper cell commitment to Th1 
phenotype. They belong to a positive feedback loop promoting Th1 cytokine secre-
tion, leading to Th1 development (Kashiwakura et al., 1999; Szabo et al., 2000). TBX21 
downregulation in Sezary syndrome would explain the previous observation of the 
loss of the chemokine ligand CXCR3 expression along the progression of mycosis 
fungoides (Lu et al., 2001), because TBX21 regulates the CD4+ cell traffi cking via 
CXCR3 (Lord et al., 2005). 
In SS PBMC samples, the expression of SCYA5 (RANTES) and NKG7 was down-
regulated. These genes have also been linked to Th cell differentiation and shown to 
be more abundantly expressed in cells polarized to Th1 than Th2 direction (Nagai et 
al., 2001; Lund et al., 2005). SCYA5 is a chemokine that mediates the traffi cking and 
homing of T-cells (Appay et al., 2001). Very little is known about the functional role of 
NKG7 in the Th cell differentiation. NKG7 is expressed in activated T cells in periph-
eral blood (Turman et al., 1993). It is induced by IL-4 in the early stages of differentia-
tion process, but later on its expression is upregulated also by IL-12. After one week of 
polarization, NKG7 is preferentially expressed by Th1 cells (Lund et al., 2005).
Among the upregulated genes, several genes important for the early polarization 
of T helper cells into Th2 direction (Lund et al., 2005) were identifi ed, e.g. S100P and 
LIR9 genes. Increased expression of S100P was observed in both SS and MF PBMC 
samples. S100P has a role in cell cycle progression and differentiation, and its up-
regulation has been found in various malignancies (Guerreiro Da Silva et al., 2000; 
Diederichs et al., 2004; Sato et al., 2004; Hammacher et al., 2005). Because an ex-
pression bias for S100P was found in mycosis fungoides blood samples also, S100P 
may have a role in the early oncogenesis of CTCL. In addition, membrane-bound 
LIR9 (215838_at) was overexpressed in SS PBMC, MF PBMC, and MF CD4+ sam-
ples. LIR9 is a member of leukocyte immunoglobulin-like receptor family mostly ex-
pressed on monocytes and neutrophils but not on normal T cells. In monocytes, acti-
vation of LIR9 induces secretion of IL-1β, tumor necrosis factor-α, and IL-6 (Borges 
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et al., 2003). Deregulation of tumor necrosis factor signalling pathway has been linked 
to both Sezary syndrome and mycosis fungoides pathogenesis (Tracey et al., 2003; 
French et al., 2005), and IL-6 has been shown to be a marker of SS tumor burden and 
to correlate with clinical stage in non-leukemic CTCL (Hassel et al., 2004). Moreover, 
IL-6 is an important cytokine for Th2 cell differentiation (Diehl et al., 2002) and also 
induces S100P (Hammacher et al., 2005). 
Of the cytotoxicity-associated genes, XCL1 (lymphotactin), GZMB (granzyme 
B), and VAV3 were downregulated. XCL1 is known to augment antitumor responses 
(Cairns et al., 2001), and VAV3, like the other two VAV proteins, functions specifi cally 
in signaling pathways that trigger natural killer cell cytotoxicity (Cella et al., 2004). 
KIR3DL2 (CD158K), a member of the killer cell immunoglobulin-like receptors, has 
been suggested previously as a phenotypic marker for Sezary cells (Poszepczynska-
Guigne et al., 2004) and has been found upregulated in Sezary syndrome (van Doorn 
et al., 2004). Contradictory, in this study the KIR3DL2 gene was downregulated in 
Sezary syndrome samples. The discrepant observations of KIR3DL2 may be due to 
the considerable polymorphism of the KIR3DL2 gene (Dohring et al., 1996; Gardiner 
et al., 2001), or may refl ect the fact that only about half of the expanded T-cell clones 
express CD158K and that CD158K expression is heterogeneous even within the ma-
lignant clones (Ortonne et al., 2006).
IL-2Rβ was downregulated in Sezary syndrome blood samples, which is of inter-
est because IL-2 is the major cytokine for T-cell activation and proliferation. IL-2R 
consists of three subunits, of which IL-2Rβ and IL-2Rγ are expressed on resting T 
cells and upregulated by IL-2. The high/intermediate affi nity IL-2R is expressed on ca.
50% of CTCL cells (Jones et al., 2004). Consequently, IL-2-targeted therapy has been 
used for CTCL, most recently with a fusion protein denileukin diftitox (ONTAK; Du-
vic et al., 1998). Interestingly, the retinoid X receptor retinoid, bexarotene, a new ther-
apeutic agent for mycosis fungoides (Duvic et al., 2000), upregulates both the α and 
β subunits of IL-2R. This, in turn, enhances the susceptibility of the malignant cells 
to denileukin diftitox, resulting in overall response rates of 67% in relapsed CTCL 
patients (Foss et al., 2005). These fi ndings indicate that changes observed by gene ex-
pression profi ling may be applied for the development of novel targeted therapy.
The expression levels of IL-7R, but not IL-7, were upregulated in the lesional skin 
biopsies of mycosis fungoides patients, and immunohistology revealed that the origin 
of the increased IL-7R was in the basal keratinocytes and infi ltrating lymphocytes in 
CTCL lesions. IL-7 is used as growth factor for CTCL cell lines that are extremely diffi -
cult to propagate (Dalloul et al., 1992; Möller et al., 1996; Döbbeling et al., 1998). IL-7 
has also been shown to increase IL-7R expression on Sezary cells (Foss et al., 1994). 
Knockout studies in mice suggest that IL-7R has an important role in differentiation 
and activation of T lymphocytes as well as in blocking apoptosis (Maraskovsky et 
al., 1996; Akashi et al., 1997). In CTCL, inhibition of apoptosis might also provide a 
growth advantage to the malignant T-cells in the skin. Since IL-7 has a role in traffi ck-
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ing of T lymphocytes to and from the skin (Williams et al., 1997; Jiang et al., 2005), 
the IL-7/IL-7R balance might infl uence the homing of malignant lymphocytes to the 
epidermis in CTCL. Thus, a plausible molecular explanation for the proliferative re-
sponse of CTCL cells to skin-derived IL-7 was revealed (Foss et al., 1994).
CD52 upregulation was found at both transcriptional and protein level. Immu-
nohistochemistry revealed CD52 protein expression of skin-infi ltrating lymphocytes 
of early stages mycosis fungoides (stages IA-IB). CD52 membrane antigen is normally 
expressed on all lymphocytes, but its actual function is unclear. Nevertheless, human-
ized anti-CD52 monoclonal antibody (Campath-1H, alemtuzumab) has been used to 
treat advanced forms of CTCL (Sezary syndrome and late-stage mycosis fungoides; 
Ravandi et al., 2005). This fi nding might warrant the use of alemtuzumab also for 
earlier stages of mycosis fungoides, in case its adverse effects allow. 
MMP-9 upregulation was observed in SS and MF PBMC samples, whereas MMP-9 
protein was demonstrable in skin infi ltrating lymphocytes in SS but not in MF skin biop-
sies. This might indicate that the original malignant clone arises in blood and thereafter 
homes to the skin. In infl ammatory dermatoses, the lymphocytes did not express MMP-
9. In addition to their role in facilitating tumor cell invasion and metastasis (Overall et 
al., 2002; Klein et al., 2004), MMPs may be involved in cancer initiation possibly by ac-
tivating intracellular mediators that are inducers of genomic damage and may cause ge-
nomic instability (Egeblad et al., 2002). Concordantly, MMP-9 overexpression has been 
previously observed in MF in relation to an advancing stage (Vacca et al., 1997). 
Dysregulation of genes located in chromosomal areas showing DNA copy number 
aberrations were of special interest. The SNCA gene, mapping to chromosome 4q21 
frequently amplifi ed in CTCL (Mao et al., 2002), was upregulated in all studied tissues 
or cell types of MF and SS patients. SNCA is a major component of protein aggregates 
present in Parkinson’s disease (Kim et al., 2004). Although some genes linked to Parkin-
son’s disease may also have aberrant expression levels in cancers (West et al., 2005), such 
a connection has not been found for SNCA so far. However, overexpression of SNCA has 
been shown to increase cell proliferation (Lee et al., 2003). The DLG5 tumor suppressor 
gene (Woods et al., 1989; Nakamura et al., 1998), found to be downregulated in SS sam-
ples, is located in 10q23, a chromosomal area frequently deleted in CTCL (Scarisbrick et 
al., 2000; Mao et al., 2002). This gene has a role in cell growth control and maintenance 
of cell adhesion and cell polarity (Woods et al., 1993 and 1996). Downregulation of 
DLG5 has previously been observed in several neoplasms (Cavatorta et al., 2004; Tani-
uchi et al., 2005), and our fi nding reinforces its function as tumor suppressor.
In this data set, there were differences compared to previously reported fi nd-
ings by Kari and coworkers and by van Doorn and coworkers (Kari et al., 2003; van 
Doorn et al., 2004). The two signifi cantly overexpressed genes in the Dutch sample 
set, EPHA4 and TWIST1 (van Doorn et al., 2004), were not differentially regulated 
in these SS and MF blood cells compared to control samples. Increased expression 
of PLS3 (T-plastin) or JUNB in SS as has previously been reported (Su et al., 2003; 
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Mao et al., 2003), was neither observed. Instead, a statistically non-signifi cant STAT4 
downregulation of average expression level was observed in SS and MF PBMC sam-
ples and MF CD4+ samples as previously reported (Showe et al., 1999; van Doorn et 
al., 2004). The causes for these discordances are discussed in 5.1.
Identifi cation of single, aberrantly expressed genes not only allows the better un-
derstanding of the pathomechanisms of the disease, but may also provide diagnostic 
aid. The usage of microarray results in clinical diagnosis has recently been demon-
strated with a 5-gene QPCR assay including STAT4, GATA-3, PLS3, CD1D and TRAIL 
developed to aid in the diagnosis of SS (Nebozhyn et al., 2006). Assays including only 
a single gene would be easier to implement in the SS diagnostics, but the variation in 
expression patterns among patients has been too great to allow single gene diagnos-
tics. For instance the expression of T-plastin alone was informative only to 50 percent 
of the patients in the study of Nebozhyn and coworkers (2006), has been even lower 
(30 percent) in previous array studies (Kari et al., 2003), and unreported in some 
studies (Ortonne et al., 2007; Study II).
Table 7 (presented in Study II) summarizes the presumed consequences of the 
gene expression changes observed in this study. These fi ndings provide the basis for 
future development of similar diagnostic or prognostic assays. Before the clinical use 
of such assays, the markers need to be validated among a larger patient material. 
Table 7. Genes found to be differentially expressed and relevant to CTCL pathogenesis. 
Gene designation Finding Molecular function Presumed function or expected 
functional consequence in 
CTCL
TBX21 (T-bet) Downregulated Transcription factor Th1 down
SCYA5 (Rantes) Downregulated Chemokine Th1 down
NKG7 Downregulated Th differentiation Th1 down
XCL1 Chemokine,
(lymphotactin) T-cell cytotoxicity (CTL)
TXK Downregulated Transcription factor Th1 down
GZMB (granzymeB) Downregulated T-cell cytotoxicity Th1 down, lack of CTL activity
S100P Upregulated Th2 polarisation, cell cycle 
and differentition
Th2 up
LIR9 Upregulated Membrane receptor, induces  
IL-1 , TNF-  and IL-6
Th2 up
KIR3DL2 Downregulated Membrane receptor Lack of CTL activity
IL2R Downregulated Cytokine receptor Impaired immune response
VAV3 Downregulated Signal transduction, activates 
e.g. Rho family
Disturbed T cell activation
DLG5 Downregulated Tumor suppressor Increased cell proliferation
MMP-9 Upregulated Matrix metalloproteinase, 
regulates angiogenesis




CD52 Upregulated Membrane antigen Target molecule of alemtuzumab
MS4A4A Upregulated Membrane antigen Signal transduction in 
haematopoietic cells
Downregulated Th1 down, lack of CTL activity
IL7R Cytokine receptor Lymphocyte activation and 
homing to epidermis
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4.3.3 Copy number and expression of genes encoding receptor 
tyrosine kinases (KIT, PDGFRα, VEGFR2) is different between 
the CTCL-associated and primary lung cancers (IV)
Inspired by the fi nding that CTCL-associated lung cancers demonstrated DNA copy 
number gains in chromosome arm 4q, whereas reference lung cancers showed losses 
in that arm, three receptor tyrosine kinase genes located adjacent at 4q12 were selected, 
and their copy numbers were studied by FISH and protein expression by IHC. FISH 
showed increased copy number of KIT gene in three CTCL-associated lung cancer sam-
ples and in one reference lung cancer sample. PDGFRα gene was coamplifi ed with KIT 
in all of the above cases, and VEGFR2 coamplifi cation was evident in secondary lung 
cancers but not observed in the reference lung cancer sample with KIT and PDGFRα 
amplifi cations. Both of the CTCL-associated SCCs showed increased copy numbers of
KIT, PDGFRα, and VEGFR2, whereas none of the reference SCC samples did. The 
KIT protein expression was also demonstrated in these CTCL-associated SCC sam-
ples, whereas it was absent from the reference SCC samples. In the reference lung 
cancer samples, KIT deletions were neither observed, but chromosome 4 monosomy 
was evident in approximately one third of the nuclei thus explaining the DNA copy 
number loss in chromosome 4q observed by CGH in two samples. (Study IV, Table 3 
and Figure 3.)
KIT, PDGFRα and VEGFR2 genes, encoding receptor tyrosine kinases, are of ma-
jor clinical interest, since they are the targets for tyrosine kinase inhibitor therapy (e.g. 
imatinib mesylate). In CTCL, the KIT expression is reported to be very rare (Brauns et 
al., 2004), but in lung cancers, KIT amplifi cation or overexpression has been observed 
in small cell lung cancer (Sihto et al., 2005) and pulmonary large-cell neuroendocrine 
carcinoma (LCNEC) resembling SCLC (Rossi et al., 2005), but not in NSCLC (Sekido 
et al., 1991). Interestingly, both CTCL-associated NSCLC cases but none of the refer-
ence NSCLC cases demonstrated increased KIT gene copy numbers together with 
KIT protein expression. To date, PDGFRα and VEGFR2 amplifi cations have not been 
reported in NSCLC, which is characterized by deregulation of mainly EGFR family 
tyrosine kinases (Bunn et al., 2006). Thus, the fi nding of  PDGFRα and VEGFR2 gene 
copy number increase in CTCL-associated SCC samples, but not in primary SCC 




5.1 Validity of the methods
Molecular genetic studies on CTCL have been hampered by the diffi culty of obtaining 
suffi cient numbers of the truly malignant, clonal cells. They are often are sparse in the 
early CTCL stages, and their propagation in vitro has proven diffi cult. Additionally, in 
the skin, the cancer cells are interspersed within the reactive lymphocytes and other 
normal cells of the skin. The focus of this thesis has been to allocate studies to the true 
malignant cells. This was achieved by laser microdissection of picking the morpho-
logically malignant cells (Studies III and IV), or by combining the data from differ-
ent tissues and cell populations of the same individual patients (Study II). Through 
this approach, the genetic changes characteristic to the cancer cells (microdissection-
based method) or characteristic to the whole tumor microenvironment (combination 
of different cell types) were assessed.
Due to the aforementioned, the availability of research material from CTCL pa-
tient -derived tissues was problematic during the course of this study. The amount of 
genomic material achieved by microdissection of single cells was too sparse to allow 
any further studies without whole genome amplifi cation. The method of Stoecklein 
and coworkers (2001) was chosen to reliably amplify the microdissected DNA. The 
whole genome amplifi cation succeeded but the amplifi ed DNA was not suitable for a 
reliable genomic microarray analysis. 
Especially, the usage of microarrays has brought a lot of data, but the results are 
not uniform due to the different experimental designs, practically varying probe and 
sample sets as well as the variability in the analysis methods (Marshall et al., 2004). 
Interestingly, Kari and coworkers discovered that panels of fewer than 10 genes can 
be used to classify CTCL cases and separate them from controls even when the Sé-
zary cell count is as few as 5% (Kari et al., 2003). This might indicate that even a 
small proportion of morphologically malignant cells is able to produce factors that 
induce CTCL-specifi c expression pattern (Wood, 2005) or that the actual malignant 
transformation of the cell occurs before the cell turns morphologically malignant 
(Karenko et al., 2001). In the future, methods selectively picking up the morphologi-
cally and/or immunohistologically/karyotypically malignant cells should be used also 
in the microarray analyses. Combination of DNA and RNA copy number changes 
(as performed in Study II) detected by microarray techniques would provide further 
knowledge of the poorly known aetiology of CTCL, as well as provide new diagnostic 
and therapeutic tools. 
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5.2 The pathomechanisms of CTCL
5.2.1 NAV3 in the pathogenesis of CTCL
A new gene was identifi ed to be recurrently deleted or translocated in association with 
CTCL. This gene, NAV3, is hypothesized to be a haploinsuffi cient tumor suppressor 
increasing IL-2 production in CTCL cells. IL-2 induces T cell proliferation by activat-
ing STAT5 (Moriggl et al., 1999), and the sustained expression of an IL2-inducible 
truncated STAT5 protein may allow Sezary cells to escape IL-2 activated cell death 
(Mitchell et al., 2003). Thus, the malignant T-cells would have a defect in activation 
induced cell death which forms the basis for the survival of the early malignant T-
cell. Whether also allelic NAV3 loss contributes to the STAT imbalance, remains to be 
seen. At the moment, the function of NAV3 is studied by gene expression profi les in 
NAV3-silenced target cells (neural, epithelial and lymphoid cells) and animal models 
are being generated. According to preliminary fi ndings, NAV3 would have a role in the 
mitotic process and, thus, its deletion could be linked to aneuploidy. Moreover, in the 
glioblastoma cells, preliminary results indicate co-localization of the embryonic stem 
cell transcription factor NANOG and NAV3 (Carlsson et al., abstract, 2006). NANOG 
is a transcription factor, essential for the pluripotent phenotype and the self-renewal 
of human embryonic stem cells. It is not expressed in adult tissues, except for various 
cancers, and has been shown to accelerate cell proliferation. Further characterization 
and identifi cation of NAV3-regulated genes and signalling pathways in different hu-
man cells and tissues is in progress by using targeted NAV3 silencing with oligonu-
cleotide and lentiviral siRNA techniques. Also, the possible association of NAV3 with 
other stem cell -related proteins warrants further studies.
NAV3 is also aberrated in other cancers than CTCL (Study I), lung cancer (Study 
IV), and neuroblastoma (Coy et al., 2002), the majority of which are of epithelial 
origin (Krohn et al., unpublished). LOH of some microsatellite markers at the chro-
mosomal band 12q21, but not specifi c for the NAV3 region, has been shown to occur 
in pancreatic carcinoma (Kimura et al., 1998). Thus, NAV3 might be important for 
early carcinogenesis functioning in cancers of different origins and, thus, the ongoing 
studies focusing on the identifi cation of NAV3-associated signalling pathways will be 
important.
5.2.2 T helper cell balance and CTCL
This study identifi ed down-regulation of a panel of Th1-specifi c genes, e.g. TBX21, 
SCYA5, NKG7, XCL1 (lymphotactin), TXK, and GZMB (granzyme B) in Sezary syn-
drome samples by gene expression analysis. These fi ndings provide basis for previous 
observations of a preferential Th2-type cytokine profi le in SS. Moreover, downregula-
tion of the major Th1 polarizing transcription factor TBX21 was for the fi rst time as-
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sociated with CTCL. Its expression was lowered in PBMC samples of both Sezary syn-
drome and mycosis fungoides patients. Down-regulation in the expression of SCYA5 
(RANTES) and NKG7 were observed also among some of the MF PBMC samples. 
TBX21, TXK, and XCL1 regulate the key cytokine secreted by the Th1 cells, IFN-γ, 
which has previously shown to be absent from the chromosomally clonal (i.e. true 
malignant) cells in Sezary syndrome (Karenko et al., 2001). GZMB promotes Th1 dif-
ferentiation by infl uencing IL-12 secretion, and interestingly, GZMB is reported to be 
absent from the chromosomally clonal cells in skin and lymph node samples of Sezary 
syndrome (Karenko et al., 2001). The genes upregulated during the early polarization 
of T helper cells into Th2 direction (Lund et al., 2005) and upregulated in both Sezary 
syndrome and mycosis fungoides PBMC samples included the S100P and LIR9 genes. 
They both act via IL-6 to promote Th2 type immune response. 
These fi ndings not only confi rm that Th1/Th2 balance regulates CTCL patho-
genesis (Vowels et al., 1992 and 1994; Dummer et al., 1996), but also suggests that 
bias towards Th2 type immune response takes place already in the mycosis fungoides 
stage, prior to progression to the leukaemic phase. This kind of a skewing is likely to 
infl uence the progressive immune dysregulation in CTCL and would thus provide a 
growth advantage for the malignant cell clone(s) (Cosmi et al., 2004).
5.2.3 Histogenesis of SPTL
This study clarifi ed the classifi cation of cutaneous T-cell lymphomas. When the study 
was begun, subcutaneous panniculitis-like T-cell lymphomas were classifi ed among 
aggressive CTCL subtypes (Willemze et al., 1997) and were often treated with heavy 
chemotherapy. Later, two different T-cell subgroups were distinguished with different 
clinical features and prognosis (Willemze et al., 2005 and 2008). This study reinforced 
that the current classifi cation is relevant also at molecular cytogenetic level. 
There are speculations about the true nature of SPTL. According to one theory, it is 
a continuum of lupus erythematosus profundus, rather than a cutaneous lymphoma. 
Since both SPTL and lupus panniculitis are characterized by a lobular panniculitis, 
the histological differentiation among these is usually diffi cult. Also, the constitution-
al symptoms of many SPTL patients are similar as in systemic lupus erythematosus. 
Several similarities in the histopathology of SPTL and lupus panniculitis (LEP, lupus 
erythematosus profundus) have been observed, namely lymphoid atypia with pleo-
morphic cells, erythrophagocytosis, histiocytes, eosinophilic necrosis of the fat lob-
ule, loss of certain pan T-cell markers (e.g. CD3, CD5, CD7, CD8), a reduced CD4/8 
ratio in the skin and clonal TCR rearrangement (Magro et al., 2001). In contrast, the 
most useful histopathologic criteria for distinguishing LEP from SPTL are the pres-
ence of involvement of the epidermis, lymphoid follicles with reactive germinal cent-
ers, mixed cell infi ltrate with prominent plasma cells, clusters of B lymphocytes, and 
polyclonal TCR-gamma gene rearrangement in LEP (Massone et al., 2005). Because 
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of the diffi cult differential diagnosis of these two panniculitis forms, it is suggested 
that patients with lupus panniculitis and atypic cell infi ltrates should be prospectively 
followed (Cassis et al., 2004). In this study, a large number of CTCL-specifi c chromo-
somal aberrations was identifi ed, discouraging the usage of the term “continuum of 
LEP” for SPTL. Future studies on a larger sample material of SPTL suitable for aCGH 
or expression array studies are likely to even identify single target genes or molecules 
applicable for e.g. clinical diagnostics.
These current fi ndings also provide new information on the usage of systemic 
steroids as a fi rst line therapy for SPTL. While it took almost ten years to reach the 
defi nite SPTL diagnosis for three of the fi rst cases, they were all treated with oral ster-
oids for unclassifi ed panniculitis and long-lasting remissions, even for 10 years, were 
achieved. Moreover, three of the more recent patients have responded completely to 
long-term systemic steroid therapy. The factors determining response to sole high-
dose systemic corticosteroid therapy and the requirement of multi-agent chemother-
apy need to be defi ned in a larger prospective study, however. 
Autoimmune phenomena occur frequently among SPTL patients (Willemze et 
al., 2008). Five of the nine cases had an autoimmune disease or presence of laboratory 
abnormalities suggestive of an autoimmune disorder. It is noteworthy that the au-
toimmune phenomena of four of the fi ve cases completely disappeared after the suc-
cessful treatment of SPTL with multiagent chemotherapy. This observation supports 
a link between the autoimmune disorder and the development of SPTL. However, 
such association still needs to be confi rmed in a multinational prospective study.
5.2.4 The development of CTCL-associated lung cancer
Chromosomal aberrations in CTCL-associated lung cancers were identifi ed to re-
semble CTCL-specifi c chromosome changes rather than those typical of lung cancer. 
The fact that there are so many molecular cytogenetic similarities between CTCL and 
CTCL-associated lung cancer supports the hypothesis of an existing precursor cell 
that may lead to both cancer types (Figure 6). An alternative mechanism explaining 
the association of lung cancer with CTCL could be related to an interaction between 
the epithelial cells and surrounding lymphocytes, the landscaping effect, leading to 
malignancy, as has been recently described in colon cancer (Kim et al., 2006).
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Figure 6. Hypothesis of the development of CTCL-associated lung cancer from a bone-
marrow-derived cancer stem cell.  Bonemarrow -derived stem cells migrate to the sites 
of tissue damage in skin and lungs where they become tissue-specifi c stem cells and are 
prone to malignant transformation. 
5.3 Clinical relevance of the novel CTCL target genes
The diagnosis of CTCL is diffi cult. Especially the lack of clearly defi ned criteria to dif-
ferentiate early MF from benign infl ammatory disorders is by far the most diffi cult, 
debated and yet crucial issue. The current diagnosis is based on clinical, histopatho-
logical and molecular genetic criteria but when additional genetic and molecular 
information in CTCL patients become available and their prognostic implications 
determined, further revisions to the diagnostic criteria will be needed (Olsen et al., 
2007).  
Current CTCL therapies are based on a variety of unspecifi c mechanisms 
(Trautinger et al., 2006). Most therapies, e.g. PUVA, bexarotene and extracorporeal 
photopheresis, induce apoptosis of CTCL cells. Successful therapies with bexarotene 
and ONTAK lead to a Th1 favoured balance. Monoclonal antibodies against CD52 
(alemtuzumab) and IL2R (ONTAK), as well as interferon induce cytotoxic immune 
response against the cancer cells. None of these therapies is curative, because they are 
not able to target the pure malignant cells.
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5.3.1 NAV3 in CTCL diagnosis
This study demonstrated a novel FISH-based diagnostic test for CTCL (Study I). De-
letion of NAV3 can be demonstrated on interphase nuclei from archival patient de-
rived material either fresh frozen or stored in liquid nitrogen, or more easily, from 
paraffi n-embedded tissue blocks by FISH technology. Alternatively, LOH methods 
may be used when DNA from both affected and unaffected tissue is available. Be-
sides for diagnostic purposes, demonstration of NAV3 aberration would be used as 
a biomarker to monitor the response to therapy and to detect early relapses of the 
disease. Follow-up studies to reveal the role of NAV3 aberrations as such biomarker 
are ongoing. 
5.3.2 Membrane antigens as targets for therapy
The few monoclonal antibodies available at the moment target either CD52 (alem-
tuzumab), IL2R (Ontak), or CD4 molecules (zanolimumab). The usage of antibody-
based therapy requires the malignant cells to express the certain membrane antigen. 
Monoclonal antibodies are easy to prepare (David et al., 1990; Nikolova et al., 2001), 
and thus suitable therapy means targeted against membrane proteins. In the gene 
expression analysis (Study II), upregulated genes included MS4A4A and LIR9, which 
would become novel targets for antibody-based therapy. MS4A4A belongs to the 
MS4A superfamily (Liang et al., 2001), another member of which (CD20) is already 
now the target of monocloncal antibody -mediated therapy in large B-cell lymphoma 
(Press et al., 1987).
5.3.3 Chromosomal areas likely to harbor new target genes
In this study, CTCL gene expression profi ling was for the fi rst time combined with the 
moleculocytogenetic fi ndings refl ecting DNA copy number aberrations. Through this 
approach, chromosome arms were identifi ed where both gene expression and DNA 
copy number was changed to the same direction (i.e., 1q, 3p, 3q, 4q, 12q, 16p, and 
16q). Thus, the above chromosome arms are potential targets for searching for further 
recurrent gene aberrations in CTCL.
Regarding CTCL, chromosome 4 is interesting. It belongs to the frequently ampli-
fi ed (Mao et al., 2002) and overexpressed (Study II) chromosome arms. Interestingly, 
CTCL-associated lung cancers showed DNA copy number gain in 4q, and amplifi ca-
tion and protein expression of genes located in 4q12, even though primary lung can-
cers are characterized by DNA copy number loss in chromosome 4q (Study IV). KIT, 
PDGFRα, and VEGFR2 genes, receptor tyrosine kinases, located adjacent in chromo-
some band 4q12 were expressed differentially among CTCL-associated and reference 
lung cancer. Additionally, SNCA gene, mapping to 4q21, was up-regulated in all stud-
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ied tissues or cell types of mycosis fungoides and Sezary syndrome patients (Study II). 




This study was initiated in the early 2000’s at the golden time of cancer genetics in-
spired by the completion of the Human Genome Project (Lander et al., 2001; Venter 
et al., 2001).
The fi rst two substudies aimed at characterizing the genes involved in the patho-
genesis of the most common CTCL subtypes, MF and SS. The purpose of substudies 
III and IV was to characterize the more rare subtypes of CTCL, including SPTL and 
CTCL-associated lung cancers.
NAV3 gene aberrations occur in many CTCL subtypes and a diagnostic test for 
the demonstration of allelic NAV3 loss in patient-derived tissue samples was devel-
oped. Since then, NAV3 aberrations have been observed in human malignancies of 
different origin suggesting its crucial function in oncogenesis.
Gene expression profi ling revealed several novel genes involved in CTCL patho-
genesis and potential therapeutic targets. Downregulation of a set of genes involved 
in Th1 polarization, including the major Th1-polarizing factor, TBX21, was for the 
fi rst time associated with CTCL. Molecules relevant for skin homing were revealed 
by observing increased expression of IL-7R and CD52 in MF but not in SS samples. 
Furthermore, chromosomal arms with both gene copy number and gene expression 
level changes were identifi ed as potential targets for searching for further novel target 
genes.
Aberrated chromosomal regions in morphologically malignant SPTL cells were 
identifi ed differentiating this subtype from the commonest subtypes. Aberrations in 
chromosome regions 10q, 17p and 19 are common to many CTCL subtypes (MF, SS, 
and SPTL), and are likely to harbour genes common for the molecular pathogenesis 
of several subtypes of CTCL. Instead, 5q and 13q gains characterize SPTL.
CTCL-associated lung cancers show chromosomal aberrations different from 
primary lung cancer, especially amplifi cations of 4q, a chromosome arm frequently 
deleted in the latter tumor type. Moreover, copy numbers and expression of selected 
genes in chromosome 4 differed between CTCL-associated and reference lung cancers. 
These observations suggest common underlying factors between CTCL and CTCL-
associated lung cancer and warrant further prospective studies to identify them.
Taken together, several novel candidate molecules for more accurate diagnosis of 
CTCL as well as targeted therapy were identifi ed. To evaluate the suitability of these 
molecules for clinical practise is the mission for the next few years. 
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